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Abstract
Quantum dots offer a number of advantages over standard fluorescent dyes for moni-
toring biological systems including high luminescence, stability against photobleaching,
and a wide range of fluorescence wavelengths from blue to infrared depending on the
particle size. In this work, we investigated in using the protein cage apoferritin as a
template for the synthesis of colloidal quantum dots.
We obtained apoferritin after reductive dissolution of the ferritin iron core and
showed that the protein structure was left intact during this process. We further studied
the solubility of ferritin, apoferritin and cationized ferritin in organic and fluorinated
solvents by hydrophobic ion pairing methodology in order to expand the possibility of
using an apoferritin template for the synthesis of quantum dots in organic media.
We then focused on the synthesis and fluorescence properties of PbS quantum dots
in aqueous solution. PbS dots are thermally stable and emit in the range 1,100 to
1,300 nm depending on their size. We demonstrated the encapsulation of these PbS
quantum dots within the cavity of the iron storage protein apoferritin using two routes:
1) the disassembly/reassembly of apoferritin subunits trapping previously synthesised
PbS quantum dots; and 2) use of the channels present in the protein shell to allow the
entrance of Pb2+ and S2− ions leading to formation of quantum dots in the apoferritin
cavity. We show that PbS-apoferritin composites emit in the near infrared region which
make them promising labels for biological applications.
Furthermore, we demonstrated that PbS QDs can be excited via a bioluminescence
resonance energy transfer (BRET) using luciferin from Luciola mingrelica which could
be developed into a self-illuminating labelling system.
vi
Finally, in order to make PbS-apoferritin composites selectively attachable to biomol-
ecules during labelling experiments, the apoferritin was modified by the incorporation
of analogues of methionine introducing azido groups absent in the proteins. The azido
groups can then be selectively modified in complex mixtures e.g. cell lysates using
‘bio-orthogonal’ reactions such as the Cu(I) catalysed Staudinger ligation and Huis-
gen cycloaddition. This would allow highly selective addition of receptor targeting or
cellular permeation of peptides to the outer surface of the apoferritin shell.
Keywords: quantum dots, PbS, apoferritin, photoluminescence, colloidal nanocrys-
tals, template, near infrared, BRET, un-natural amino acid.
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Chapter 1
From Physics & Chemistry to
Nanobiotechnology
In the past decade, fluorescent proteins and organic fluorophores have been widely used
for biological labelling. In addition to these materials, detection of macroscopic molec-
ular targets is now possible using a variety of metal-based nanoparticles.[1–3]
The first nanoparticle was reported in 1570 in the form of aurum potable (potable gold)
and luna potable (potable silver).[4] As early as 1971, colloidal gold particles were used
as labels for microscopic localization of biomolecules. The ability of nanogold to be
covalently attached to antibodies gave them the possibility to be linked specifically to a
second biomolecule such as proteins (the prion protein responsible for the Creutzfeldt-
Jacob disease (CJD)), peptides (calmodulin - the protein regulating the calcium re-
lease), drugs, viruses, carbohydrates, lipids, and nucleic acids (Figure 1.1).[4]
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Figure 1.1: Two major lipid classes covalently bound to gold clusters. Commercially avail-
able palmitoyl nanogold (fatty acid-gold) and diphosphatidyl ethanolamino (DPPE) nanogold
(phospholipid-gold).[5]
The term nanotechnology is employed to describe the creation and exploitation of
materials with structural features in between those of atoms and bulk materials, with
at least one dimension in the nanometre range (Figure 1.2).[6, 7]
Figure 1.2: Sizes of representative ‘small’ objects. (a) a cockroach; (b) a human hair; (c)
polygonum pollen grain; (d) red blood cells; (e) cobalt nanocrystal superlattice; (f) an aggregate
of half-shells of palladium; (g) aspirin molecule.[7]
Nanomaterials have led to a massive worldwide investment both in scientific knowl-
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edge and in commercial applications (Figure 1.3).[8, 9]
Figure 1.3: Where is the money going? (right): (a) percentage breakdown of nanotechnology
venture deals from 1998 to 2003; (b) distribution of venture capital funding in nanotechnology
from 1998 to 2003.[8]
In the medical field, pulmonary diseases due to inhalation of inorganic particulate
matter such as asbestosis and coal miner’s disease, have increased the interest in the
nanoscale particle regime for pulmonary toxicologists.[10, 11] They report that nano-
scaled materials are more toxic than equivalent micron-sized materials at similar doses
per gram of body weight, particle composition and surface chemistry. However, al-
though nanoparticles have been reported to enter the human body through several
ports (skin, lungs, intestines), depending on the surface characteristics and the size of
the particles, it is thought to be unlikely that exposure to nanomaterials would pose
any substantial risk to public health.[11, 12]
1.1 Semiconductor nanocrystals as fluorescent labels
Semiconductor nanocrystals, also called quantum dots (QDs), are nanostructures that
confine the motion of an electron in all three spatial dimensions. This gives rise to a
set of discrete electronic energy levels, similar to those in atomic physics.
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1.1.1 Quantum confinement in a nanocrystal
To describe the energy levels and electronic wavefunctions of a QD, it is necessary to
apply the principles of quantum mechanics and solve the Schro¨dinger equation by taking
into account the shape, composition and size of a QD. For a basic understanding of
the atomic-like quantization of the electronic states of a dot into discrete energy levels,
here we consider a dot of spherical shape (Figure 1.4).
Figure 1.4: Schematic representation of spherical polar coordinates.
The Schro¨dinger equation for a particle in a spherical potential can be solved by
using spherical polar coordinates as shown in Figure 1.4 and can be written as:
− h¯
2
2me
~∇2ψ(r, θ, φ) + U(r)ψ(r, θ, φ) = Eψ(r, θ, φ) (1.1)
where h¯ is the reduced Planck’s constant (h¯ = h/2π), me is the effective mass of
electron, U(r) is the confinement potential energy and E the total energy. The solution
of equation (1.1) can be written as the product of an angular term Y (θ, φ) and a radial
term R(r):
ψ(r, θ, φ) = R(r)Y (θ, φ) = R(r)Θ(θ)Φ(φ) (1.2)
Using this expression for ψ, equation (1.1) leads to three equations for R(r), Θ(θ) and
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Φ(φ). The solution gives rise to three quantum numbers n, l and ml:
d
dr
(
r2
dR
dr
)
− 2mlr
2
h¯2
[U(r)− E]R = l(l + 1)R (1.3)
sinΘ
d
dΘ
(
sinΘ
dΦ
dΘ
)
+ l(l + 1) sin2ΘΦ = m2l Θ (1.4)
d2Φ
dΦ
= −m2l Φ (1.5)
The solution of equation (1.3) exists only if the principal quantum number n = 1, 2, 3, ....
The solution of equation (1.4) exists only if the orbital quantum number l = 0, 1, 2, 3, ...n−
1.
The solution of equation (1.5) exists only if the magnetic quantum number ml =
−l, ...+ l.
For an infinite spherical potential well,
V (r) =


0 if r ≤ a
∞ if r > a
where a is the dot radius. The eigenvalues are given by:
En,l =
h¯2
2mea2
β2nl (1.6)
where βnl is the n
th zero of the lth spherical Bessel function.
Figure 1.5 represents the variation of the energy En,l for n = 1 and l = 0 upon the
dot radius, a, for an electron confined in a spherical PbS QD.
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Figure 1.5: Dependence of the energy En,l on the radius, a, of a spherical PbS QD.
For a PbS spherical dot of radius a = 5 nm, we find that the energy of the electron
ground state is E1,0 = 0.189 eV. Here, we have used the effective mass of the electron
me = 0.08m
0
e where m
0
e = 9.11 × 10−31 kg and β1,0 = 3.15. A similar confinement
energy H1,0 can be found for the holes. The electron-hole recombination energy can be
expressed as hν = E1,0+H1,0+Eg where Eg is the energy gap of bulk PbS (Eg = 0.41
eV at 290 K). Using this expression for hν, we find that hν = 0.788 eV for a = 5 nm.
1.1.2 Excitons
In semiconductors, an exciton is a Coulomb-correlated electron-hole pair. This quasi-
particle can be created in a solid crystal by photon excitation: a photon can excite
an electron from the valence band into the conduction band leaving behind a hole of
positive charge. The Coulomb interaction between the two particles results in a bound
electron-hole pair with average distance called the exciton Bohr radius, Rexc, in anal-
ogy with the Bohr radius for atoms describing the distance between the nucleus and
the orbiting electron. An exciton can be described using the same formalism used to
describe an hydrogen atom. However, the Bohr radius of an exciton is much larger
than that of an H-atom (a0 = 0.05 nm) due to the effect of screening of the atoms in
the crystal and the effective mass of the carriers.
To account for these effects, we express Rexc as:
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Rexc = ǫr
m0e
µ
a0 (1.7)
where µ is the reduced mass of the exciton (µ−1 = m−1e +m
−1
h , where me and mh are
the effective masses for electrons and holes), ǫr is the relative permittivity and m
0
e is
the electron mass in a vacuum.
For PbS, ǫr = 17.2, µ = 0.04m
0
e and Rexc = 21 nm. Table 1.1 reports the Bohr
radii of different semiconductor materials. Since the exciton Bohr radius tends to be
larger than the size of a QD (< 10 nm), excitons are strongly confined in nanocrystals
thus leading to efficient light emission and absorption.
II-VI materials III-V materials IV-VI materials
ZnS CdSe GaAs InAs PbS PbSe
3 6 12 34 21 46
Table 1.1: Bohr radii of semiconductor materials in nanometre.
The band gap of a quantum dot is usually tunable as it can be altered by the addi-
tion or subtraction of one or more atoms to the semiconductor nanocrystal. Therefore,
the exciton emission wavelength can be modified leading to a wide range of coloured
nanocrystals. By altering the QD size and its chemical composition, fluorescence emis-
sion can be tuned from the near ultraviolet, throughout the visible, and into the near
infrared spectrum, spanning a broad wavelength range of 400-2,000 nm (Figure 1.6).[13–
18]
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Figure 1.6: Tuning of the quantum dot emission depending on their chemical composition.[19]
1.1.3 Quantum dots compared to organic fluorophores
Conventional organic dyes have been extensively used as bioprobes for labelling and
imaging both in vivo and in vitro for more than three decades.
As an example, a classification-colouring karyotyping of all human chromosomes was
established in 1996 by Ried et al. using five different organic fluorophores (Cy2, Spec-
trum Green, Cy3, Texas Red, and Cy5 or combinations of these) to give a multicolour
spectral imaging (Figure 1.7).[20]
Figure 1.7: Spectral karyotyping of human chromosomes. (A) Presentation of display colours.
(B) Presentation of spectra-based classification colours. Regions rich in repetitive sequences.
(C) Karyotype of the classification-coloured metaphase chromosomes shown in (B).[20]
More recently, Bradley D. Smith’s group reported the use of a near infrared carbo-
cyanine dye to image the bacterial infection by S. aureus in a living mouse as shown
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in Figure 1.8.[21]
Figure 1.8: Optical images of a mouse with a S. aureus infection in the left rear thigh muscle
labelled with an organic fluorophore.[21]
Nevertheless, with the emergence of quantum dots, the efficiency of organic chro-
mophores (portion of a molecule that is directly responsible for absorbing photons) has
been exceeded. In Table 1.2, the properties of QDs are compared to those of traditional
fluorophores.
Property Fluorescent probe Quantum dot probe
1 Broadband excitation × √
2 Narrow bandwidth emission × √
3 Emit light of high intensity moderate
√
4 Available in many colours
√ √
5 Readily attachable to analytes
√
moderate
6 Resistant to quenching × √
7 Photochemically stable × √a
a quantum dots are prone to blinking.
Table 1.2: Comparison of the properties of conventional fluorophores and quantum dots.[22]
Since 2000, the supply of colloidal quantum dots has increased remarkably with
the emergence of technological companies. Quantum dots with a variety of conju-
gates and colours are currently available from Quantum Dot Corporation (Hayward,
CA, USA)[23], Evident Technologies (Troy, NY, USA)[24], Invitrogen (Carlsbad, CA,
USA)[25] and Nanoco Technologies (Manchester, UK)[26].
It is important to note that QDs permit multiplexed analysis. Broadband excitation
and narrow bandwidth emission allow simultaneous excitation of multicolour QDs with
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a single light source. In 2002, Chan and Nie quantified a different emission intensity
of 20:1, i.e., one quantum dot emits the same amount of light as 20 rhodamine 6G
molecules. They established that single dots are ∼ 100-200 times more stable than
single organic dye.[27, 28] Figure 1.9 gives an example of the differences observed in
the emission and excitation spectra of a quantum dot and an organic dye.
Figure 1.9: Comparison of (a) the excitation and (b) the emission profiles between rhodamine
6G and CdSe quantum dots (adapted from reference [27]).
Concurrently to organics dyes, fluorescent proteins (FPs) were discovered from var-
ious marine organisms.[29] For example, the AFPs (Aequorea-derived fluorescent pro-
teins) family has been engineered from the green fluorescent protein (GFP). The GFP,
represented in Figure 1.10, is comprised of 238 amino acids (26.9 kDa) and fluoresces
green (λem = 509 nm) when exposed to blue light.[1, 30, 31]
Figure 1.10: Green fluorescent protein ribbon diagram.
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However, the main problem with the use of GFP was the excitation and emission
spectra of the wild type protein for fluorescence microscopy. Wild type GFP shown in
Scheme 1.1 has two excitation peaks: a major one at 395 nm (protonated form of the
protein) and a smaller one at 475 nm (unprotonated form).
Scheme 1.1: Cyclization in the tripeptide Ser65Tyr66Gly67 followed by dehydrogenation and
oxidation lead to the formation of the green fluorescent protein.
To alleviate this problem, several mutants of the GFP were constructed into mutants
such as cyan (CFP) and yellow (YFP) variants with increased fluorescence and red-
shifted major excitation peaks.
1.1.4 Synthesis of colloidal quantum dots
There are several techniques for nanoparticle synthesis including MBE (molecular beam
epitaxy), lithographic patterning and colloidal synthesis. Here, we will focus on colloidal
synthesis.
The advantages of the chemical synthesis of nanoparticles are multiple: 1) different
sizes of nanocrystals can be obtained with high monodispersity by controlling the reac-
tion conditions and reagent ratios, 2) chemical absorption or surface chemical reactions
can be used to passivate the surface states to obtain high quality QDs, 3) the colloidal
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method of growth allows the manipulation of the QDs into optically clear solutions or
polymer films, as well as the possible attachment to a metal surface or various template
structures.[32–34]
For many years, quantum dots have been synthesised in organic media. The ligands
TOP (trioctyl phosphine) and TOPO (trioctyl phosphine oxide) are frequently used as
stabilizing ligands as they can coordinate both metal and chalcogen elements (S, Se,
Te).[35–38] The major drawback of TOPO is its high boiling point (320 ◦C) and its
flammability (Scheme 1.2).
Scheme 1.2: Schematic representation of the synthesis of TOPO-capped CdSe quantum
dots.[38]
Nevertheless, the organic ligands are labile for exchange reactions because of their
weak bonding to the nanocrystal surface atoms and give imperfect surface passivation.
Therefore, the strategy established for increasing both the fluorescence and the sta-
bility of QDs in organic media is to grow a shell of higher band gap semiconductor
surrounding the core. Currently, the most popular QDs consist of CdSe core, followed
by a ZnS shell and one or more organic coats.[39, 40]
During the synthesis of nanocrystals (NCs), two phases of kinetic growth are ob-
served as depicted in Figure 1.11:
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Figure 1.11: Mean size and size distribution of two types of QDs CdSe and InAs (adapted
from reference [41]). The arrows 1 represent the first injection of precursors and the arrows 2
represent a second injection of precursors.
Over the first few minutes of the reaction, the average size of the QD increases rapidly
and the size distribution decreases, this is called ‘focusing of size distribution’; then,
the nanocrystals grow more slowly, the smaller nanocrystals are dissolved and are rede-
posited on the larger nanocrystals, thus the overall average size of the QDs increases and
the size distribution broadens, this is called ‘defocusing’ or ‘Ostwald ripening’.[36, 41]
An important landmark in the development of wet chemical synthetic routes for
cadmium chalcogenide nanocrystals was, together with the non-aqueous TOP/TOPO
technique, the use of various thiols as capping agents in aqueous solution.[42–44]
A series of thiol-capped CdSe,[44] CdTe,[42, 45] and CdS[43] nanoparticles were syn-
thesized with extremely small sizes (1-3 nm) in aqueous solution. Nanoclusters were
obtained through the addition of freshly prepared NaHSe, NaHTe or H2S solutions to
N2-saturated Cd
2+ precursor solutions (Cd(ClO4)2
.6H2O or CdSO4) at pH 11.2 in the
presence of thioacids or thioalcohols as stabilizing agents. Following this procedure, col-
loidal HgTe nanocrystals have also been prepared by the passage of hydrogen telluride
gas H2Te through aqueous N2-saturated mercury(II) perchlorate Hg(ClO4)2 solutions
at pH 11.2 in the presence of thioglycerol (Figure 1.12).[46]
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Figure 1.12: Representation of the synthesis of thiol-capped CdTe QDs. I) formation of CdTe
precursors by introducing H2Te gas. II) formation and growth of CdTe nanocrystals promoted
by reflux.[45]
The idea to introduce colloidal quantum dots into living cells for biological labelling
has emerged from their photophysical properties and from the realisation that QDs are
the size of a typical protein (Figure 1.13).[19, 47]
Figure 1.13: Size comparison of QDs and comparable objects, fluorescein isothiocyanate
(FITC), quantum dot (qdot), quantum rod (qrod), streptavidin (SAV), maltose-binding protein
(MBP), immunoglobin G (IgG).[18]
Currently, the use of semiconductor nanocrystals for diagnostic applications is a
rapidly developing research field of nanotechnology.[48–52] Indeed, quantum dots are
the most promising nanostructures for testing technologies that meet the clinical labora-
tory medicine demands for sensitivity and cost-effectiveness.[53–55] Quantum dot-based
diagnostics have the potential to be more cost-effective than existing technologies.[56–
59] “Biologists have always had to figure out what they could do in the first 5 or
10 minutes before the dye ran out. Now they can look for much longer” says Paul
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Alivisatos, a chemist at the University of California, Berkeley and one of the founders
of Quantum Dot Corporation.[23]
1.1.5 Modifying quantum dots with biological tags
The potential of colloidal semiconductor nanocrystals to overcome problems encoun-
tered by organic fluorophores make them useful elements/components for optical, elec-
tronic and biological applications.[53, 60–70] Scientific interest in interfacing of tech-
nology and biology is based on the principle that nanotechnology offers biology new
tools, and that biology offers nanotechnology new types of functional scaffolds.[71]
As emphasized by S. Weiss of the University of California, Los Angeles, a founder of
Quantum Dot Corporation “We need to protect the quantum dots so that they are
not oxidized, are very stable, can withstand salt concentrations in cells, and do not
bind to what you do not want them to”.[48] Thus, for successful biological assays, the
nanocrystals must be hydrophilic and not interfere with normal physiology, as well as
being stable, exhibiting narrow fluorescence peaks, and having a high quantum yield
(QY1). Importantly, they would also be size-tuneable in the near infrared spectral range
if they are to be used in vivo.[72–76] As shown in Figure 1.14, the range 600-1,100 nm
is the ‘optical window’ of biological systems where the main components of the cells
(H2O, melanin and haemoglobin) have their lowest absorption coefficients.[77]
1Probability of luminescence occurring in given conditions - expressed by the ratio of the number
of photons that are emitted by the luminescent species to the number of photons that are absorbed.
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Figure 1.14: Absorption spectra of intracellular absorbers. The molecular extinction coeffi-
cients (ǫ) of oxygenated haemoglobin and melanin and the absorption coefficient (α) of water
are shown.[77]
One current major drawback of QDs is that they are not easily linked to biomolecules
that can be used to target receptor, improve solubility or cell permeability. The use of
bioinorganic conjugates - QDs/protein systems - could overcome this problem and there-
fore represent an attractive tool as a novel method for use as bioactive fluorescent probes
in sensing, imaging, immunoassays, and other diagnostics applications.[19, 59, 78–87]
In 1998, two research groups, Alivisatos et al.[89] and Nie et al.[56], reported the first
use of quantum dots nanocrystals to label single molecules during living-cell assays and
this topic is now being intensively investigated.
Different types of bioconjugated systems are schematically illustrated in Table 1.3:
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Method of
Linker Scheme Information Referencesattachment
to QD
Silanization
Biotin-avidin
• In 1998, Alivisatos et al. were the first
[88–90]
group to report the bioconjugation of
silica-coated CdSe/CdS core-shell NCs
to mouse fibroblast cells.
Bifunctional
• The cross-linker possesses an ester
[91–93]
function at one end, which reacts with
a primary amine of a biomolecule to
form a stable amide bond and a
maleimide group at the other end, which
reacts with a sulfhydryl group of the
dots to form a stable thioether bond.
Covalent linkage Amide
• In 1998, Chan and Nie established
[56, 94–99]
the second class of adaptor using an
amide linker between nanoparticles
and biomolecules.
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Hydrophobic • Exchange of the hydrophobic
[100–105]ligands TOP/TOPO ligands with thiolated
exchange biomolecules.
Metal- • In 2005, Mattoussi et al. described a
nitrogen linkage of poly-histidine terminated [106]
coordination proteins with QDs.
Metal- • Polysaccharides directly bound to the
oxygen QDs surface by Zn-O bond. [107]
coordination
Covalent
• QDs encapsulated in phospholipid
[108–118]micelles can be selectively coupled to
Hydrophobic a sulphydryl group of a biomolecule.
attraction
Biotin-avidin
• Commercial polymer-coated QDs
[23, 119–127]functionalized with streptavidin
available from Quantum Dot Corp.
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MBP-zb
• Electrostatic attraction between
[128–132]
negatively charged QDs and positively
charged leucine zipper interaction
domain of the maltose-binding protein.
PG-zb
• Maltose-binding protein is used as a
[133, 134]
Electrostatic purification tool and protein G (PG-zb)
attraction as a molecular adaptor to attach
the QDs to an IgG.
(-) • Electrostatic interactions between
[104, 130, 132, 135]
QDs/ negatively charged semiconductor NCs
(+) and positively charged avidin
biomolecules which can be attached to biomolecules.
Table 1.3: Conjugation systems between quantum dots and biomolecules.
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It should be noted that the surface of a single QD is large enough for linking to
multiple biomolecules. Approximately 15-20 maltose binding proteins can be attached
to the surface of a 6-nm diameter CdSe/ZnS QD whereas a 3-nm CdSe/ZnS QD could
be covered with ∼ 12-15 MBP.[19, 27]
Many other applications of quantum dots as labels in biological applications have
been reported in the literature.[136–168] Biomolecule-nanoparticle hybrid systems com-
bine the unique optical and electronic properties of QDs (size-dependent excitation and
emission wavelength, resistance to photobleaching2, high quantum yield in aqueous so-
lution) with naturally optimized recognition and reactivity functions of biomolecules.
This self-assembly approach applied to a wide range of semiconductor nanomaterials
employing other recombinant proteins should result in a considerable array of biosen-
sors with various useful properties.
Protein cages can provide structurally constrained reaction environments.[169–175]
In our project, we are interested in using the widely studied iron storage protein, ferritin,
as a template for the preparation and protective functionalisable coat of inorganic
nanomaterials.
1.2 Ferritin, the iron storage protein
The iron storage protein, ferritin plays a key role in iron metabolism.[176–178] Two
and a half billion years ago, the solubility of iron became a problem when water began
to be used as a source for photosynthesis:
6CO2(gas) + 6H2O(liquid)
light−−−→ C6H12O6(aqueous) + 6O2(gas). The by-product of such
synthesis - dioxygen - created a dilemma for iron-dependent organisms; either to move
to media devoid of dioxygen or change to accommodate the low solubility of FeIII
produced from FeII by dioxygen oxidation (the solubility of FeIII is 10−9 that of FeII).
The role of ferritin is to maintain and store iron in a soluble and available form for use
2irreversible destruction of a fluorophore that is under illumination.
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as ferrihydrite [FeIIIO.OH].[179–181]
1.2.1 Ferritin structure
Ferritins are found in both eukaryotes (humans, other vertebrates, invertebrates, higher
plants, fungi) and prokaryotes (bacteria).[182] Although the primary sequences of fer-
ritin show significant differences among species, the three dimensional conformations
are found to be strikingly similar in all cases except for the bacterioferritin (for details,
see reference [183]).
In 1962, Harrison and Hofmann suggested that this protein consists of 20 identical
subunits.[184–186] Now it is known that all ferritin molecules consist of a protein shell
called apoferritin (AFt), composed of 24 polypeptide subunits (total molecular weight of
ca. 480 kDa),[187–192] and a central core of hydrated iron(III) oxide [FeIIIO.OH][193,
194]. The apoferritin subunits assemble into a hollow sphere with an outer diameter of
12 nm, and an inner core of 8 nm in diameter (Figure 1.15).
Figure 1.15: Schematic representation of the ferritin structure.
Up to 4,500 iron atoms can be encapsulated within the protein shell to give ferritin,
although normally only 2,000-2,500 iron atoms are present in the form of microcrystals
as shown by electron and X-ray diffraction[195] and high-resolution dark-field electron
microscopy[196]. Thus, ferritin is characterised as an inhomogeneous protein due to the
iron content that varies from one ferritin molecule to another (molecular weight around
750,000 for high loading).[197, 198] The iron core is generally thought to be formed
from oxidation of Fe2+ upon admission of oxygen, resulting in Fe3+ which hydrolyzes
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within the cavity.[181, 199–201] In addition to iron, the mineral core of various ferritins
also contains phosphate in variable amounts influencing the size of the core.[202]
The apoferritin shell is an heteropolymer composed of a variable proportion of two
subunits designated by H (for heavy or heart, molecular weight 21,000) and L (for light
or liver, molecular weight 19,000). Differences in the subunits of apoferritin are due
to variations in the sequence of amino acids throughout the chain, in chain length,
and in mass.[203, 204] Ferritins isolated from vertebrates are composed of two types of
subunit (H and L), whereas those from plants and bacteria contain only H-type chains,
where H-chains are important for FeII oxidation and L-chains assist in core formation.
Furthermore, the relative proportions of H and L subunits appears to be organ specific,
heart generally giving a higher proportion of H subunit, while liver and spleen ferritins
contain mainly the L subunit.[179–181, 205–208]
In our study, the protein cages used are the horse spleen apoferritin and the human
liver apoferritin whose DNA sequences are reported in Table 1.4.
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1 60
Horse H MTTAFPSQVRQNYHQDSEAA I NRQ I NLELHASYVYL SMS FYFDRDDVALKNFAKYFLHQS
Human H MTTASTSQVRQNYHQDSEAA I NRQ I NLELYASYVYL SMSYYFDRDDVALKNFAKYFLHQS
Horse L MS SQ I RQNYS TEVEAAVNRLVNLYLRASYTYL S LGFY FDRDDVALEGVCHFFRELAEEKR
Human L MS SQ I RQNYS TDVEAAVNSLVNLYLQASYTYL S LGFY FDRDDVALEGVSHFFRELAEEKR
61 12
0
Horse H HEEREHAEKLMKLQNQRGGR I FLQD I KKPDQDDWENG LKAMECALHLEKNVNESLLELHK
Human H HEEREHAEKLMKLQNQRGGR I FLQD I KKPDCDDWESG L NAMECALHLEKNVNQSLLELHK
Horse L EGAERLLKMQNQRGGRALFQDLQKP SQDEWGTT LDAMKAA I VLEKS LNQALLDLHALGSA
Human L EGYERLLKMQNQRGGRALFQD I KKPAEDEWGKTPDAMKAAMALEKKLNQALLDLHALGSA
12
1
18
0
Horse H LATDKNDPHLCDFLETHYLNEQVKA I KELGDHVTNLRRMGAPESGMAEYLFDKHTLGECDES
Human H LATDKNDPHLCDF I ETHYLNEQVKA I KELGDHVTNLRKMGAPESGLAEYLFDKHTLGDSDNES
Horse L QADPHLCDF LE SHFLDEEVKL I KKMGDHL TN I QR LVG S QAGLGEYL FERLTLKHD
Human L RTDPHLCDF LETHFLDEEVKL I KKMGDHL TNLHR LGGP EAGLGEYL FERLTLKHD
Table 1.4: DNA sequences of both H and L apoferritin from horse and human. The discrepancies between species are highlighted in red.
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Both of the H horse and human subunits contain approximately 182 amino acids
whereas both of the L subunits contain 175 amino acids (Table 1.5). After biosynthesis,
the first methionine residue (shown in green in Table 1.4) is removed.
Amino acid
No. residues subunit
Horse H Horse L Human H Human L
Asp 14 12 15 13
Glu 18 15 16 16
Lys 13 9 13 12
Arg 8 11 7 10
Asn 11 6 12 6
Gln 10 11 10 7
Ser 9 10 12 8
Thr 6 6 7 7
Phe 8 8 6 8
Trp 1 1 1 1
Cys 3 2 3 1
His 11 6 10 7
Tyr 7 6 9 7
Gly 7 11 7 12
Ala 13 15 13 15
Val 6 8 6 6
Leu 22 28 22 27
Ile 5 4 6 3
Met 6 4 5 5
Pro 4 2 3 4
Table 1.5: Amino acid composition of H and L subunits of horse spleen apoferritin and human
liver apoferritin.[209, 210]
Furthermore, each subunit of apoferritin is folded in a bundle of two pairs of α-helixes
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joined by a long loop (Figure 1.16):
Figure 1.16: Schematic representation of the horse spleen ferritin molecule. (A) Subunit
arrangement. (B) Conformation of the horse spleen apoferritin subunit showing alternative
connectivities between helical sections (adapted from reference [181]).
Each subunit is roughly cylindrical (l = 5.5 nm, d = 2.7 nm)[211] and contains four
long nearly parallel right-handed helices (A, B, C, D), a shorter helix (E), a helical turn
(P), a long length of extended chain (L), some regions of irregular conformation and a
N -terminus (N). Helices A-E are joined in alphabetical order and L connects opposite
ends of B and C. The N -terminus is on a short non-helical region preceding A. Helix
A on the outside of the molecule turns into B on the inner surface; following the long
loop L, the polypeptide chain runs along C on the outside of the subunit, and after
a tight corner turns along D on the inside surface, then via a twisted segment and a
single helical turn P, the chain ends with E.
Ferritin is a thermally stable protein up to 82 ◦C. Granick observed some changes
in ferritin when a dialyzed protein solution was slowly heated.[212, 213] Coagulation
occurred at T = 82 ◦C which redissolved on cooling, whereas at higher temperatures,
the protein was irreversibly denatured.
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1.2.2 Electrostatic features
One of the most interesting feature of the apoferritin shell is the presence of channels
formed by the different types of interactions of the 24 subunits (Figure 1.17).[193, 214]
Figure 1.17: Schematic representation of the hydrophobic and hydrophilic channels of
apoferritin.[215]
These channels are responsible for the entrance and exit of cations. Eight hydrophilic
channels - referred to as 3-fold channels - are formed by interactions of three N -terminus
of glutamate and aspartate residues and six hydrophobic channels - referred to as 4-
fold channels - are formed by interactions of twelve leucine residues (three from each
subunit) (Figure 1.18).
Figure 1.18: Structures of the amino acids L-aspartate (Asp), L-glutamate (Glu) and L-leucine
(Leu).
The presence of charged amino acids gives specific electrostatic potential to the protein.
The potential on the interior surface is, like the outer surface, mostly negative with only
a few regions with an excess of positively charged amino acids.[216]
The external entrance of the 3-fold channel has a negative potential value due to the
presence of glutamic acid and aspartic acid residues. These acids are also responsible
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for the negative potential along the channel across the protein shell from the outside
to the inside. Furthermore, the outer entrance is surrounded by regions of positive
potential values giving rise to an electrostatic field directing cations toward the channel
entrance. This channel might function as a funnel to direct cations into the apoferritin
cavity.
The potential on the exterior of the 4-fold channel tends to be positive due to the
presence of the free N -terminal amino acid amine, thus resulting in a repulsive surface
to positively charged ions. It has been proposed that this channel may function as a
pathway for the removal of cations (Scheme 1.3).
Scheme 1.3: Schematic representation of the channels across the protein shell.
Many studies have been performed investigating the permeation of small molecules
into apoferritin but with conflicting results.[217–219] Diffusion studies have shown that
glucose (7 A˚ across) is capable of slowly entering the interior of the ferritin capsule,
but sucrose (approximately twice the size of glucose) is not.[220, 221] On the contrary,
X-ray studies have shown that maltose (13 A˚) can enter into the cavity of ferritin
through the channels (3-4 A˚) which implied that the latter are sufficiently flexible to
allow entrance of molecules larger than their own size.[222]
1.2.3 Dissociation of the protein shell subunits
The first demonstration that apoferritin could be converted into subunits was made
by Hofmann and Harrison in 1962, using the anionic detergent SDS (sodium dodecyl
sulphate) and other denaturants. Furthermore, ferritin and apoferritin were not affected
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by the addition of 10 M urea. However, the optical rotatory properties changed in
presence of 6 M guanidine hydrochloride at pH 6.0 consistent with helix disruption in
the protein.[185, 188, 223, 224]
By far the most useful procedure for the reversible dissociation of apoferritin is that
described by P. M. Harrison and D. W. Gregory in 1965 in which they observed the
disassembly of the protein shell into its subunits as a function of pH.[225] In 1968,
they also showed that apoferritin subunits are able to assemble in the absence of
iron as determined by electrophoretic mobility and sedimentation coefficient analyses,
which led to the conclusion that the reassembled apoferritin is identical to the native
ferritin.[226, 227]
Crichton and Bryce studied the dissociation of apoferrritin by sedimentation veloc-
ity techniques and established that between pH 2.8-10.6 the apoferritin is only present
as a 24 subunit capsule whereas between pH 1.6-2.8 and 10.6-13.0 both the capsule and
a low molecular weight component were detected.[228] The dissociation into subunits
is more easily observable by 1H NMR analysis at low pH and it has been shown that
at pH ∼ 3.5, ferritin starts to dissociate and at pH ∼ 1.8, the protein is completely
dissociated.[229] This phenomenon can be explained by the subunit-subunit interac-
tions. At low pH values, one tryptophan residue per subunit as well as four to five
tyrosine residues per subunit are exposed to the solvent. These transfers are accompa-
nied by the protonation of the different carboxyl groups present on the subunit. During
the reassociation process at high pH values, the carboxyl groups are deprotonated and
the sequence described above is reversed. The extreme stability of the apoferritin is
due to intersubunit hydrophobic interactions and surface charges.[230]
As ferritins are robust proteins that can withstand high temperature (82 ◦C) and
high pHs (8.5-9.0) for an appreciable period of time, this dissociation-reassociation
process of the protein shell is an attractive asset in order to entrap small molecules
inside the cavity. Effectively, the apoferritin shell can be dissociated into subunits at
pH 2.0 in the presence of the nanomaterials and then by increasing the pH to 7.0 the
subunits reassemble into the 24-subunit shell, thereby trapping molecules within its
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interior.
1.3 Apoferritin as a protein cage for quantum dots
Preparation of semiconductor nanocrystals in a controlled manner is a very interest-
ing challenge as their optical and electronic properties depend on the size, shape and
chemical composition of the particles. One possible issue for the preparation of an
ideal isolated nanomaterial involves the use of a preorganized matrix as a chemically
and spatially confined environment for its construction.
For several years, Stephen Mann, Director of the Centre for Organised Matter
Chemistry at the University of Bristol, has been interested in using biological systems
as templates for materials synthesis.[81, 231–236] He has been working on the encap-
sulation of different types of nanoparticles in the cavity of apoferritin and his results
illustrate that the protein cavity can be a preferred environment for non-hydrolytic
reactions.
The procedures currently used to entrap small molecules within the cavity of fer-
ritin are the channels providing pathways for the entry and expulsion of ions and the
dissociation-association process of the protein shell according to the pH.
1.3.1 Entrapment of materials in apoferritin: The nanoreactor route
Although only phosphate-containing iron cores of ferritin are able to bind incoming
metal ions with high affinity, a wide number of dicationic metals (M2+) such as Cd2+,
Zn2+, Cu2+, Ni2+, Co2+, Mn2+ and Mg2+ have been reported to bind to phosphate-free
apoferritin.[237]
In 1991, Mann and co-workers established for the first time the use of protein
structures as reaction cages to generate nanoscaled materials. His group synthesized
iron(III) sulphide loaded-apoferritin by transformation of the hydrated iron(III) oxide
core to an iron sulphide in alkaline reactions conditions (in situ chemical reaction of
native oxide cores with H2S or Na2S) (Scheme 1.4).[238, 239]
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Scheme 1.4: Representation of the use of ferritin in the synthesis of nanophase materials. (a)
iron sulphide; (b) manganese oxide reconstitution; (c) uranyl oxyhydroxide deposition (adapted
from reference [240]).
Four years later, the demetallation-reconstitution process was also used to accumu-
late FeS nanoparticles within the protein cavity.[241]
By modifying the iron core, iron phosphate, arsenate, vanadate and molybdate
could be synthesised within the apoferritin.[242]
Mann and Meldrum demonstrated an in vitro synthesis of magnetoferritin - apo-
ferritin loaded with iron oxide magnetite (Fe3O4) cores (Scheme 1.5). Two prepara-
tion techniques were established: reconstitution of apoferritin with FeII solution was
achieved in 1992 under slow oxidation conditions (high temperature 60 ◦C and pH
8.5)[243, 244] and in 1998, a new synthesis was reported involving incremental addi-
tion of FeII followed by stoichiometric amounts of the oxidant triethylamine-N -oxide
Et3NO.[245]
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Scheme 1.5: Synthesis of the magnetoferritin (adapted from reference [243]).
Using ion uptake methodology, manganese ions have been deposited as Mn oxyhy-
droxide cores MnOOH (Scheme 1.4).[238, 239] Mann pointed out the roles of the inner
and outer surfaces of ferritin proposing that the outer surface acts as a polyelectrolyte
inhibiting the formation of MnOOH in the external phase whereas the inner surface is
inactive enabling nucleation and growth within the cavity.[246]
Uranyl oxyhydroxide cores (6 nm) have also been accumulated in apoferritin cavity
by ion-binding and hydrolytic polymerization. Uranyl acetate
UO2(CH3COO)2
.2H2O reduced by sulphonic acid at pH 8.0 led to 4,000 U atoms
accumulating in the apoferritin cavity (Scheme 1.4).[238, 239] In 1992, J. Hainfeld
reported the accumulation of 800 uranium atoms by incubation of uranyl acetate in
pH 4.0 buffer. The encapsulated uranium atoms had reduced toxicity and antibodies
could be attached to the outer shell for tumour imaging.[247]
Since the beginning of the 21st century, more and more researchers have been in-
terested in the use of apoferritin as a confined environment for the encapsulation of
nanoparticles.
Cobalt has been synthesized as cobalt(III) oxyhydroxide CoOOH within the protein
cage by oxidative hydrolysis of CoII with hydrogen peroxide H2O2.[248–250] Nickel and
chromium have been accumulated as their metal hydroxides through an hydroxylation
process using carbonate ions.[251] Ni and Cr cores were formed by adding Na2CO3
to ammonium nickel(II) sulphate hexahydrate (NH4)2Ni(SO4)2
.6H2O and ammonium
chromium(III) sulphate dodecahydrate NH4Cr(SO4)2
.12H2O, respectively. HCO
3−
ions substitute the coordinate water molecules and form a complex which penetrate
into apoferritin through the channels. In the cavity, HCO3− is decomposed into CO2
and OH− accelerating the hydroxylation process. Gold sulphide particles were also
incorporated by mixing Au2S and apoferritin at RT at pH 6.0-9.0.[252]
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In 2005, Domı´nguez-Vera reported loading apoferritin with CuII which entered by
the channels and, then can react with [Fe(CN)6]
3− resulting in CuII-CN-FeIII Prussian
blue (PB) nanoparticles (Scheme 1.6).[253]
Scheme 1.6: Preparation of the PB CuII-CN-FeIII-loaded apoferritin (adapted from reference
[253]).
Using the same procedure, superparamagnetic nanoparticles of nickel and cobalt have
been encapsulated within the apoferritin cavity by treatment of apoferritin with NiII
and CoII at pH 8.0. Addition of sodium borohydride NaBH4, a reducing agent small
enough to pass trough the channels led to the formation of Ni0 and Co0 particles.[254]
Mineralization of cobalt-platinum by ferritin has been achieved by adding am-
monium tetrachloroplatinate (NH4)2PtCl4 solution and cobalt acetate tetrahydrate
Co(CH3COO)2
.4H2O to an apoferritin solution at pH 8.0. Then, NaBH4 was intro-
duced to the buffered solution to reduce the metal ions precursors CoII and PtII to
form CoPt.[255, 256]
A size-selective hydrogenation catalyst has been synthesized as a Pd-loaded apofer-
ritin complex. K2PdCl4 was mixed with a solution of apoferritin at pH 8.5 and NaBH4
was added to the resulting solution for reduction of palladium.[257, 258]
More interestingly, semiconductor nanocrystallites such as CdS, CdSe and ZnSe
were formed in the cage-shaped protein. Because the cavity surface of the apoferritin
has acidic amino acid residues, the inner space has a negative electrostatic potential
which condenses the positively charged metal ion in the cavity.[216] In 1996, S. Mann
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and K. Wong prepared CdS-loaded ferritin.[259] They proceeded by the addition and
reaction of stoichiometric amounts of CdII and HS− to deaerated buffered solutions
(pH 7.5) of apoferritin (Scheme 1.7).
Scheme 1.7: Reaction scheme for the synthesis of CdS-apoferritin nanocomposites (adapted
from reference [259]).
The first step of the synthesis was the nucleation of CdS clusters inside the cavity
generated by the addition of CdII atoms followed by the addition of excess sulphide
and dialysis. These clusters were then considered as growth centres for the binding of a
second addition of cadmium and sulphide atoms. These CdS nanocrystals did not fully
develop in the cavity and the obtained CdS nanoparticles had irregular morphologies.
The UV-visible spectrum for CdS-apoferritin composites showed two absorption peaks:
an excitation peak at around 350 nm for the CdS nanoparticles and an absorption peak
at 280 nm corresponding to the peptide bonds of the protein.[260] Transmission electron
microscopy (TEM) micrographs of CdS-loaded apoferritin showed discrete electron-
dense nanometre-size particles (size estimated to be 4.5 nm and 2.5 nm at 55 and 110
CdII per molecule). Furthermore, energy dispersive X-ray analysis (EDX) confirmed
the presence of cadmium and sulphide.
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In 2004, Yamashita and co-workers reported the synthesis of uniform CdSe nanopar-
ticles within the cavity of apoferritin (509 CdSe/cavity).[261, 262] They designed a
slow chemical reaction between Cd2+ stabilized by ammonia solution (formation of
tetraaminecadmium ions Cd(NH3)4
2+) and Se2− from selenourea. The pH of this re-
action mixture was adjusted to 8.0, and then apoferritin molecules were added. This
resulted in CdSe QDs with a narrow size distribution and an average diameter of 6 nm.
In 2005, Yamashita and his group established the fabrication of 1,000 ZnSe nanopar-
ticles in one apoferritin cavity using the same procedure with tetraaminezinc ions
Zn(NH3)4
2+ (Scheme 1.8).[263] The average crystal size was determined to be 7 nm,
which is the same as the internal diameter of apoferritin cavity. The same group also
recently produced CdS encapsulated-apoferritin composites following this procedure
starting from Cd(NH3)4
2+ and thioacetic acid CH3COSH.[264]
Scheme 1.8: Schematic representation of the ZnSe-encapsulated quantum dots within the
apoferritin cavity (adapted from reference [263]).
As can be seen, a number of semiconductor nanocrystallites have been encapsulated
through the channels in the protein shell of apoferritin. In the next paragraph, the
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encapsulation of different molecules through the dissociation-reassociation process is
discussed. To date, no quantum dots have been entrapped using this methodology and
the luminescence properties of the composites reported above have not been described.
1.3.2 Entrapment of materials in apoferritin: The reassembly route
In 2002, a gadolinium complex GdHPDO3A, an extra cellular MRI contrast agent
currently used in clinical practice was introduced into the internal cavity of apoferritin
by the dissociation (pH 2.0)-association (pH 7.0) process (Figure 1.19).[265]
Figure 1.19: Representation of the gadolinium-DO3A complex.
In 2003, a new Prussian blue ferritin was reported by Domı´nguez-Vera: apofer-
ritin was loaded with a metal complex (hexacyanoferrate(III) [Fe(CN)6]
3−) by the
disassembling-reforming process, isolated and then the trapped metal complex reacted
with a second metal ion (FeII) to build a new material giving confined FeII-CN-FeIII
ferritin (Scheme 1.9).[266]
Scheme 1.9: Preparation of the PB FeII-CN-FeIII-loaded apoferritin (adapted from reference
[266]).
Larger cores could be formed by the dissociation process of the apoferritin shell. Indeed,
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using the reassembly route, the PB cores were observed to be 5 nm exhibiting an UV-
vis broad band at 710 nm, whereas the nanoreactor route described in section 1.3.1 led
to PB complexes of 3.5 nm cores with an UV-vis broad signal at 470 nm.
Desferrioxamine B (DFO) - a drug for iron chelation therapy - has been introduced
within the protein shell by dissociation of the ferritin at pH 2.0 followed by reassocia-
tion at pH 7.4. It has been shown that this DFO-loaded apoferritin could react with
FeIII to form about three [DFOFe] complexes within the cavity, this confirms that apo-
ferritin could be used as a confined environment for the construction of nanoparticles.
When apoferritin/[DFOFe] composites were synthesized by adding previously prepared
[DFOFe] complexes to apoferritin, only one [DFOFe] complex was encapsulated. These
results can be explained by the size of the hydrophilic channels (4 A˚) and by the size
of the cavity: 1) [DFOFe] complexes are much bigger than DFO molecules, thus more
DFO can be encapsulated within apoferritin cavity than [DFOFe], 2) In the case of
encapsulated DFO, FeIII atoms access to the cavity by the hydrophilic channels which
are too small to allow the release of DFO.[267]
The same procedure has also been used for the encapsulation of the marker fluoresce-
in,[269] and the drugs doxorubicin,[268] cisplatin[270] and carboplatin[270] which were
incorporated by adding the drugs to apoferritin at pH 2.0 followed by reassociation of
the subunits at pH 7.5 (Figure 1.20).
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Figure 1.20: Molecular structures of desferrioxamine B, doxorubicin, fluorescein, cisplatin and
carboplatin.
Although the efficiency of the reassembly procedure has been shown for diverse
molecules, it is important to re-iterate that this encapsulation method has not been
previously achieved for the entrapment of quantum dots within the apoferritin cavity.
1.4 Applications of apoferritin-encapsulated materials
Zborowski, Mann and co-workers reported for the first time in 1996 a new application
for a derived-ferritin composite.[271] They used magnetoferritin for immunogenetic iso-
lation of lymphocytes from mononuclear cell samples. Magnetoferritin was synthesized
as described previously.[243] Monocytes were first depleted from the cells which were
then labelled with an antibody anti-IgG (mAb). A second biotinylated antibody (Ab-
biotin) was added to the first and finally biotinylated-ferritin was attached through an
avidin bridge leading to the system cell-mAb-Ab-biotin-avidin-biotin-magnetoferritin
shown in Figure 1.21. Lymphocytes were isolated by depositing the cells on glass slides
through a magnetic field.
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Figure 1.21: Magnetoferritin used as a label for lymphocytes isolation.
Apoferritin with iron oxyhydroxide has been used for the synthesis of CrIII from
CrVI and Cu0 from CuII.[272, 273]
Ferritin can also be used as a template for the design of arrays of particles as
shown by Yamashita.[274, 275] Ferritin was deposited on a silicon substrate and then
submitted to heat treatment (450 ◦C) in order to remove the protein shell. Ordering
of iron cores was observed by X-ray powder diffraction and high resolution scanning
electron microscopy (HRSEM) before and after heat-treatment (Figure 1.22). Dried
ferritin samples contained 6 nm diameter ferrihydrite iron cores. After heating, the
core was transformed in FeO and Fe2N
.FeO. This technique could be used to fabricate
quantum electronic devices based on FeO and InO particles.[276, 277]
Figure 1.22: HRSEM images of arrays of the ferritin molecules A) before and B), C), D) after
heat-treatment under nitrogen at 300 ◦C, 500 ◦C and 700 ◦C for 1 h, respectively (adapted from
reference [274]).
Size selective olefin hydrogenation was realised using a Pd cluster incorporated in
apoferritin. Ueno et al. reported that olefin substrates could enter the cavity through
the channels and could undergo hydrogenation catalyzed by palladium (Scheme 1.10).[257]
Hydrogenation of neutral olefins was faster using the Pd/apoferritin composite than hy-
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drogenation with Pd alone. Also, the greater size or negative charge of the olefin leads
to slower hydrogenation.
Scheme 1.10: Hydrogenation of olefins by Pd-loaded apoferritin.
Cobalt-filled carbon nanotubes were prepared from cobalt-encapsulated apoferritin.
The apoferritin shell of Co-AFt composites was removed by heat-treatment leaving free
cobalt on a substrate.[278]
Recently, Iwahori and Yamashita reported the preparation of a nanodot gate mem-
ory based on apoferritin with a Co3O4 core.[279] Co/apoferritin composites were syn-
thesized following Douglas and Stark procedure.[248] The gate was prepared by a sili-
con oxide surface positively charged by poly(ethyleneimine) (PEI) on which negatively
charged Co/apoferritin composites could be deposited by electrostatic attraction. By
heat-treatment, apoferritin and PEI could be removed leaving Co nanoparticles on the
substrate. Electric measurement showed that the NP array was responsible for storage
of electrons or holes depending on the voltage.
Metallic phosphate nanoparticles encapsulated within the apoferritin cavity through
nanoreactor and reassembly routes showed good voltammetric signals for bioanalytical
applications.[280]
The conjugation of ferritin to other biomolecules have been studied by different
techniques.
Modification of the lysines residues on the outside of apoferritin have been exploited
as a method of connection. Mann et al. reported the creation of networks of ferritin
molecules by cross-linking ferritin through biotin-avidin bridges.[281] Biotinylation of
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horse spleen ferritin led to 72 modified lysines residues/ferritin molecule. Figure 1.23
shows TEM and SDS-PAGE analyses confirming the formation of networks once strep-
tavidin was added to biotinylated ferritin molecules.
Figure 1.23: TEM micrographs of A) streptavidin added to native ferritin and B) networks of
ferritin molecules formed by the addition of streptavidin to biotinylated ferritin. C) SDS-PAGE
of (1) protein marker, (2) native ferritin, (3) streptavidin, (4) native ferritin + streptavidin, (5)
biotinylated ferritin + streptavidin, (6) biotinylated ferritin (adapted from reference [281]).
Hexacyanoferrate(III)- and fluorescein-encapsulated apoferritin composites were used
as bioassay labels for the detection of DNA.[282] Eight amino-modified DNA strands
were covalently linked to the carboxylic amino acids of apoferritin through EDC (1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride) coupling.
Lysines residues were recently modified with different sized N -hydroxysuccinimidyl
ester derivatives. Four acetyl/alkyne derivatives were attached to each subunit.[283]
1.5 Project aims
This project focuses on 1) the synthesis of QDs and tuning of their properties; and
2) the encapsulation of quantum dots within the cavity of apoferritin using the two
methods described previously:
• The nanoreactor route: inorganic ions enter apoferritin cavity through the 3-4 A˚
diameter channels between the subunits of the protein shell. QDs formation is then
stimulated by the presence of a high density of aspartate and glutamate amino acid
residues on the inner surface of the protein shell (Scheme 1.11).
CHAPTER 1. From Physics & Chemistry to Nanobiotechnology 41
• The reassembly route: apoferritin shell disassembles into its subunits at pH = 2.0
and re-assembles at pH > 8.0 in the presence of preformed quantum dots in aqueous
solution (Scheme 1.11).
Scheme 1.11: Encapsulation of QDs within the cavity of apoferritin either by the channels
(upper scheme) or by the disassembly/reassembly process (lower scheme).
In the following section, the solubility of the protein ferritin in organic media, the
preparation of the protein cage apoferritin and the synthesis of PbS quantum dots are
discussed.
We show that the formed apoferritin/PbS QD composites emit in the near infrared
(NIR) wavelength range. This makes the composite an attractive tool for biological
applications as hemoglobin and water have their lowest absorption coefficient in the
NIR region where the light scattering is minimum.[75, 284]
The QDs/protein bionconjugate system could:
1) simplify the conjugation of QDs to other biomolecules (proteins, peptides, car-
bohydrates),
2) improve the QDs stability/solubility in aqueous solution,
3) reduce the immune response induced in vivo,
4) reduce the QDs toxicity in vivo,
5) control the size of the QD to ∼ 7 nm.
Chapter 2
PbS quantum dots
2.1 Introduction
Of the various nanocrystals, PbS-based QDs have emerged as promising candidates for
optical applications in the near-infrared (nir) region of the electromagnetic spectrum.[285–
288] In particular, since the wavelength emission of PbS dots can be controlled and
tailored within the spectroscopic window 900-1,200 nm of low absorption of biological
systems, water soluble PbS nanocrystals have the potential to be used as biocompati-
ble fluorescent labels to replace traditional organic fluorescent dyes in in vivo biological
applications.
2.1.1 Previous syntheses
In the literature, the synthesis of lead-sulphide nanocrystals (IV-VI materials) in aque-
ous solution has been reported where PbS cores were coated by various organic molecules
such as PVA (poly(vinyl-alcohol)), PVP (poly(vinyl-pyrrolidone)), DNA, etc.
PVA, PVP and DNA-coated PbS quantum dots were synthesized from an aqueous
solution of Pb(NO3)2 stabilized by PVA, PVP, or DNA solution at 0
◦C under argon.
H2S was added in excess to induce the formation of PbS dots.[289–291] The particle
size was generally between 4 to 12 nm and showed different particles shapes: spherical
for PVA capping, needle/cubic for PVP capping and cubic for DNA capping.
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Using the same procedure of DNA coating, Levina et al. showed that PbS/DNA
conjugates have a luminescence efficiency half-life of one week in blood plasma.[286]
Wu et al. established the synthesis of subnanometre-size PbS nanoparticles via
the electroporation of vesicles.[292] Previously dried vesicles were hydrated with a
Pb(NO3)2 aqueous solution. Na2S was added to the vesicle suspension and the precip-
itates of PbS were removed by centrifugation. The supernatant containing less than
0.4 mg mL−1 of vesicles was subjected to electroporation to form PbS quantum dots
in the bulk solution with 3-10 A˚ in diameter. Nevertheless, it was reported that PbS
QDs have a tendency to adsorb at the surface of the vesicles.
Adenosine, uridine, cytidine, guanosine triphosphates (ATP, UTP, CTP and GTP
respectively) (Figure 2.1) were also used to coat PbS QDs.[293]
Figure 2.1: Representation of ATP, GTP, UTP and CTP nucleotides.
The geometries and structures of the nucleotide GTP have been shown to play an
important role in the PbS synthesis. Only GTP was able to stabilize dots with lumi-
nescence at ∼ 1,300 nm, whereas ATP, UTP and CTP led to aggregation of particles.
Positions N2 and N7 of G have been reported to act as binding sites for Pb2+ or PbS.
Indeed, syntheses with inosine triphosphate (ITP) (G with N2 deleted) did not produce
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any PbS QDs and syntheses using a derived-compound from G (CH3 group at position
N7) showed a blue-shifted luminescence of the PbS dots.
PbS have also been synthesised microbiologically where the yeast Torulopsis has
been used as a sulphur source. Lead nitrate was added to a Torulopsis yeast culture.
After cell breakage, PbS particles were characterized as 2-5 nm nanocrystallites exhibit-
ing an absorption maximum at 330 nm. The emission maximum of the PbS dots was
not recorded, the authors reported a broad-range luminescence (350-500 nm) which
could be due to the presence of the aromatic amino acids of the microorganisms.[294]
Aptamer coated-PbS QDs were prepared by mixing thrombin-binding aptamer
(TBA) and Pb(CH3COO)2
.3H2O in TAE (Tris-Acetate-EDTA) buffer at pH 8.0, fol-
lowed by injection of Na2S.[295] The resulting conjugates are 3 to 6 nm diameter. Choi
et al. reported that the aptamer-functionalized QD binds specifically to its target, the
blood-coating human α-thrombin inducing a decrease in the PL emission of PbS QDs
due to a charge transfer where thrombin acted as a quencher.
Recently, PbS quantum dots were prepared in HEPES buffer by ligand exchange.
PbS dots were first synthesised with oleic acids ligands at 130 ◦C and transferred in
water by exchange of the organic ligands with ethylene glycol or thiol groups. These
water-soluble PbS QDs were shown to emit in the NIR region and to have a quantum
yield of 26%.[296, 297]
2.1.2 Synthesis of colloidal thiol-capped PbS quantum dots
Bakueva et al. prepared PbS quantum dots in aqueous solution using a mixture of thi-
ols, thioglycerol (TGL) and dithioglycerol (DTG), as capping/stabilizing agents (Fig-
ure 2.2).[300] The ratios between Pb, TGL and DTG have been shown to influence
the stability and the optical properties of the PbS dots. Indeed, PbS dots (Pb:TGL
6:1) with molar ratio DTG:Pb < 1:1 led to rapid growth of the dots with aggregation
and low optical features; ratio DTG:Pb > 3.4:1 involved a slow formation of the dots
(several hours); ratio DTG:Pb 1.28:1 to 3.4:1 produced stable dots with an increase in
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the emission maximum as the size increases.[298, 299]
Figure 2.2: Schematic representation of PbS synthesis using thiols: thioglycerol (TGL) and
dithioglycerol (DTG).
During the synthesis, the pH of the Pb(CH3COO)2
.3H2O solution was adjusted to
a value of 11.0 by adding triethylamine and the synthesis of the dots was completed by
adding a 0.1 M solution of sodium sulfide Na2S.
2.2 Objectives
To investigate the possibility of using near-infrared PbS QDs as biological labels, it
was necessary to study their optical stability as a function of time and temperature (4
to 300 K). Therefore, we studied the morphology and photoluminescence of a series of
thiol-capped PbS QDs in aqueous solution with Pb/S molar ratio varying from 1:0.2
to 1:0.7. This work was realised in collaboration with L. Turyanska from the Physics
Department of Nottingham University.
2.3 Results & discussion
We synthesised PbS quantum dots in deionized water with a molar ratio
Pb:TGL:DTG of 1:6:2 following the one-step method described by Bakueva et al..[301]
By varying the Pb/S molar ratio (MR) from 1:0.2 to 1:0.7, we were able to obtain
colloidal PbS dots with different sizes. The resulting colloidal solution was either kept
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in the laboratory atmosphere or stored at a temperature of 5 ◦C under N2 atmosphere.
These were examined several times over a period of six months by photoluminescence
(PL) spectroscopy at low (4 K) and room (300 K) temperature.[301, 302]
2.3.1 Morphological properties of PbS quantum dots
During the first three weeks after the synthesis, the photoluminescence maximum of
a given MR of Pb/S solution was shifted to longer wavelengths (by up to 30 nm).
This behaviour is likely to arise from Ostwald ripening effects that lead to formation of
nanocrystals with larger size and hence longer wavelength emission. This process can
be reduced by storing the solution at low temperature (T < 280 K).[302]
Figure 2.3 shows the typical RT photoluminescence spectra of the different Pb/S molar
ratios investigated:
Figure 2.3: RT PL spectra of thiol-capped PbS dots with various Pb/S MR. The optical
excitation was provided by the 514.5 nm line of an Ar+ laser.
PbS samples were analysed both as dried samples on a glass substrate and as liquid
solution in a glass vial. Under both conditions, the emission wavelength/energy values
are similar for a given molar ratio.
As expected for quantum dots, the increase in size and thus in PL emission is straight-
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forward and has a tendency to stabilize over time (Figure 2.4):
Figure 2.4: Variation of the full width at half maximum (blue) and emission wavelength (red)
of PbS dots over the time (days).
By increasing the Pb/S MR from 1:0.2 to 1:0.7, the luminescence from the PbS
dots can be tuned in the wavelength range 1,100 nm to 1,300 nm. The shift of the dot
emission towards longer wavelengths with increasing MR is due to the increase of the
QD size. Our atomic force microscopy (AFM) study, shown in Figure 2.5, indicates
that the PbS quantum dots have an approximately spherical shape with a diameter
d increasing from about 3 to 12 nm as determined from Z (heights) analysis of AFM
images for Pb/S MR increasing from 1:0.2 to 1:0.7.[302]
Figure 2.5: AFM images of PbS dots with Pb/S MR equal to 1:0.3, 1:0.5 and 1:0.7.
Figure 2.6 shows the energy of the PL peak as a function of the dot diameter:
CHAPTER 2. PbS quantum dots 48
Figure 2.6: Strong confinement of the thiol-capped PbS QDs.
Due to the strong confinement of the exciton in the dot, the PL emission peaks at
energies that are significantly larger than the band gap of bulk PbS (Eg). Also, the
emission energy tends to shift to lower energies with increasing diameter d due to a
decreasing quantum confinement potential of the exciton.
2.3.2 Optical properties of PbS quantum dots
The effect of temperature, T, on the optical properties of PbS quantum dots is of
great importance for their use in room temperature (RT ) applications. Recently, an
unusually large linewidth (∼ 100 meV) for the RT photoluminescence emission from
an individual PbS QD was reported.[303] However, the effect of temperature on the
spectral linewidth of the emission from either an individual or an ensemble of PbS dots
is still largely unknown.
Figure 2.7 shows the PL spectra at various temperatures and excitation power P = 100
W cm−2 for a representative QD sample with Pb/S MR equal to 1:0.5.[302]
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Figure 2.7: Temperature dependence of the PL spectra of thiol-capped PbS QDs with Pb/S
MR equal to 1:0.5. The insets show the T -dependence of the peak intensity (top-inset), the
energy peak, E (middle-inset), and the full-width at half-maximum, W (bottom-inset), of the
QD PL emission.
Increasing the temperature has three main effects on the PL spectrum: 1) The peak
intensity of the QD PL emission reveals a maximum at a temperature T = 50 K and
thereafter it decreases monotonically (top-inset of Figure 2.7); 2) The peak energy, E,
of the QD emission blue-shifts and its T dependence for T > 150 K can be described
by the coefficient α = ∂E/∂T = 0.3 meV K−1 (middle-inset of Figure 2.7). The value
of α is smaller than that of bulk PbS (α = 0.5 meV K−1).[304] This difference is
attributed to the atomic-like character of the dot energy levels and the strong quantum
confinement of the exciton, whose Bohr radius (20 nm)[285, 289] is considerably larger
than the dot diameter (< 10 nm).[285] 3) The blue-shift and quenching of the dot
emission are accompanied by a significant increase of the full width at half maximum,
W, of the dot emission (bottom inset of Figure 2.7).
The enhancement of the QD PL intensity observed for increasing T below 50 K indicates
a thermally activated redistribution of carriers in the dot in the presence of defects:
with increasing T, carriers (electrons or holes) trapped in a defect in or around the
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dot overcome shallow energy barriers and fall down into the ground state of the dot,
thus increasing the PL intensity. A further increase of T from 50 to 295 K decreases
the PL intensity by only a factor of 10; this T -dependence and high thermal stability
of the PL emission were observed for all our samples. These are important features
for applications and indicate a low level of thermal escape of carriers from the ground
state of the dot towards the excited states and a relatively low density of non-radiative
recombination centres.
The T -dependence of W for Pb/S solutions with different MRs is shown in Fig-
ure 2.8.[302] For T < 150 K, different T dependencies and/or values of W are observed
(W = 80-100 meV). In particular, for some structures, W exhibits a small decrease
with increasing T (see circles in Figure 2.8(a)). In contrast, for T > 150 K, all samples
show a characteristic thermally activated increase of W. This behaviour is revealed
more clearly in Figure 2.8(b) which plots W versus 1/T. It can be seen that at high T,
the T -dependence of W is well described by an exponential dependence.
Figure 2.8: (a) T -dependence of W for all samples. (b) Plot of W vs. 1/T.[302]
In order to understand the effect of the temperature on W, the mechanisms that
can give rise to the broadening of the emission from an ensemble of dots have to be
considered quantitatively.
When an atom in the crystal is submitted to excitation by photons, electrons absorb
energy and reach an excited energy level. Then, the energy is released by the electrons,
the latter either go back to the ground state or to a lower excited state and here the
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remaining energy is transmitted to the crystal lattice. In turn, the lattice reaches an
excited quantized energy level depending on the amount of energy absorbed inducing
lattice/atom vibration (Figure 2.9). In a crystal, these lattice vibrations are called
phonons.
Figure 2.9: Representation of the energy levels of the electron and the nucleus. The red arrow
corresponds to the absorption of the electron, the black arrows show the emission and the blue
and green arrows are the lost energy transferred to the nucleus that in turn reaches an excited
state.
A zero phonon line (ZPL) in a PL spectrum corresponds to an electron-hole recom-
bining without any loss of energy. A phonon sideband corresponds to an emission side
peak that appears next to the ZPL in response to the energy transferred to the crystal
lattice (Figure 2.10).
Figure 2.10: Representation of a zero-phonon line and a phonon sideband in a PL spectrum.
The gap ∆ between the ZPL and a phonon sideband is proportional to the amount of
energy transferred from the electron to the atoms in the crystal. We also note that the
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interaction of electrons with the crystal can lead to an homogeneous broadening of the
PL spectrum due to the dephasing of the electronic states. In the light of these general
consideration, we now consider our measured PL spectra.
At low T, carriers are frozen randomly into the dot states and the PL spectrum
simply reflects the distribution of the dot energies. Although the optical linewidth
depends largely on the variation of the dot size and spectral diffusion due to charge
trapping on dot defects, the thermally activated increase of W indicates that at high T
the optical linewidth is also controlled by an intrinsic scattering process due to carrier
interactions with phonons. The coupling of carriers to phonons in a QD leads to PL
emission, which consists of a ZPL and a broad band with (longitudinal optical) LO
phonon sidebands and a continuum of acoustic-phonon assisted transitions.[305–308]
The contribution of phonon sidebands to the QD PL spectrum was found to be im-
portant for CdSe QDs[305], and much weaker for nanocrystals based on (InGa)As[306]
and GaAs QDs[308]. Previous PL studies have also shown single broad PL emissions
for both individual PbS and ensembles of dots[303] with PL line shapes typically re-
produced by a single Gaussian function. Therefore, the measured thermally activated
broadening of the dot emission observed in all the PbS QDs does not arise from the
contribution of phonon sidebands, but instead from homogenous broadening of the ZPL
for each dot in the ensemble caused by interaction with the increasing thermal popu-
lation of optical phonons.[302]
The T -dependence of W can be described by the relation W = γn + W0, where
n = 1/[exp(h¯wLO/kBT)− 1] is the Bose distribution function for LO phonons of en-
ergy h¯wLO, γ is a constant and W0 represents the inhomogeneous contribution to W.
As shown in Figure 2.8(b), at high T (> 150 K) all data are well described by this
expression by setting h¯wLO equal to the energy of LO phonons in PbS (h¯wLO = 26
meV), γ = 110± 20 meV and W0 = 90± 10 meV.[304] The strength of carrier-phonon
coupling, as measured empirically by the parameter γ, tends to be larger for the dots
with the higher PL emission energies, see inset of Figure 2.11.
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Figure 2.11: Representation of a zero-phonon line and a phonon sideband in a PL spectrum.
In a QD, the interaction of electrons with phonons is expected to be qualitatively
different from that occurring in bulk systems. Inelastic interactions such as phonon-
assisted excitation of carriers to excited states or energy relaxation processes are un-
likely to occur in PbS dots as it is estimated that the confinement energy for electrons
and holes is much larger than h¯wLO.
1 In contrast, elastic collisions involving the virtual
absorption and emission of a LO phonon by carriers do not require a specific energy
separation between the discrete levels of the dot. Elastic collisions by phonons do not
change the energy of the carrier, but they do change the phase of the carrier wavefunc-
tion, thus causing a broadening of the spectral lines.[309–311] For a spherical PbS QD,
the exciton-phonon coupling strength is expected to be small due to the almost iden-
tical form and size of the electron and hole wavefunctions.[312] The calculated exciton
wavefunction and its coupling to lattice vibrations depend on the strength of carrier
confinement[313, 314] and can be influenced by local electric fields arising from trapping
of charges in QD defects[313]. An increase of the strength of carrier-phonon coupling
with increasing carrier confinement was observed in Cd(S)Se nanocrystals[315], while
an opposite trend was shown for CdTe-based quantum wells[316] and CdS QDs[317].
Our data indicate that the strength of carrier-phonon coupling, γ, is larger for
dots with the higher emission energies (> 1 eV at RT ) and smaller size (d < 7 nm)
1the estimation of the ground and excitonic transitions is based on the effective mass approximation
and a PbS nanocrystal with spherical shape of diameter d = 10 nm and infinite potential barriers.
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(see Figure 2.8(b)) in qualitative agreement with theory[314]. These dots exhibit the
largest values of W. Therefore, the local environment of the dot (i.e., trapped charges
on defects) seems to act not only to broaden the optical linewidth at low T but also
to enhance the interaction of carriers with the lattice, thus leading to an additional
broadening of the dot PL emission.
2.4 Conclusion
We have synthesised PbS quantum dots in aqueous solution emitting in the range
1,100 to 1,300 nm. It was found that by increasing the Pb/S molar ratio from 1:0.2
to 1:0.7, the size of the dot increased from 3 to 12 nm in diameter and the emission
maximum shifted to longer wavelengths. Also, we have reported that their photolu-
minescence intensity and PL peak emission were only weakly affected by temperature.
This PL stability allowed us to study the thermal broadening of the QD emission over
an extended temperature range (4-300 K). We have showed that the broadening of the
emission spectra occurring when T increased was due to phonon interaction. We also
reported that for high temperatures, the strength of the carrier-phonon coupling was
higher for smaller dots thus leading to the conclusion that at low T (T < 50 K), the
broadening of PL emission is due to the presence of defects on the surface of the dot,
while at high T, the broadening is due to trapped charges on defects as well as phonon
interactions.
Chapter 3
Preparation and characterization
of the protein cage, apoferritin
3.1 Introduction
Before exploiting the bioconjugation of ferritin with quantum dots, it was necessary to
determine the purity of the protein used through all the experiments. To this purpose,
ferritin, the cationized ferritin (surface-modified ferritin bearing additional positive
groups) and apoferritin were analysed using different techniques.
In the following paragraphs, different types of experiments (size exclusion chromatogra-
phy, SDS-PAGE, BCA, ICP-MS) have been realised in order to determine the stability
of the apoferritin during its preparation as well as the amount of residual iron in the
protein after dissolution of the mineral core.
Ferritin, a brown coloured protein, containing over 23% of ferric iron FeIII, can be
freed from its core by reductive dissolution to the ferrous state and removal of the Fe2+
by dialysis.[193] The colourless protein thus obtained is designated as apoferritin.
Two mechanisms are chemically feasible for the removal of iron from ferritin: reduction
followed by chelation of Fe(II) or direct chelation of Fe(III). Furthermore, both of these
mobilisation pathways involve the penetration of the reducing agent/chelating agent
CHAPTER 3. Preparation and characterization of the protein cage, apoferritin 56
within the cavity of ferritin to react with the iron core.
The first attempt to remove the iron core of ferritin was reported by Crichton and
Michaelis in 1943. In their experiment, they added sodium dithionite as a reducing
agent to a ferritin solution at pH 4.6 combined with o-phenanthroline or α,α′-bipyridine
to form water soluble ferrous complexes.[193]
Chelation of ferric iron is slow when biological[318–320] or synthetic[319, 321, 329, 330]
chelators as well as microbial siderophores[322–324] are used, but much more rapid
when realised with dithionite and dihydroflavins.[325–328]
Hoy et al. have studied the reductive mobilisation of ferritin iron by 1,10-phenantroline
and provided the evidence for the penetration of the reductant within the protein cavity
and its interaction with the iron core.[331]
In 1999, Mann et al. also reported the reductive mobilisation of the ferrihydrite iron core
of ferritin by mercaptoacetic acid in NaOAc buffer at pH 5.5. They synthesised deriva-
tized ferritin/apoferritin proteins in organic solvents by coupling nonylamine molecules
to the carboxyl groups present on the external surface of the protein cage.[334, 335]
More recently, aceto-, benzohydroxamic acids and catechol have been used as iron(III)-
chelating molecules to free the ferritin from its oxyhydroxide core. Domı´nguez-Vera
and co-workers showed that 60% and 18.35% of the ferric iron was removed using the
acids and catechol respectively.[332, 333]
3.2 Objectives
Our strategy to improve the stability and bioconjugation of PbS quantum dots to
other biomolecules was to incorporate them into the cavity of apoferritin. To optimise
the entrapment of QDs, we studied the efficiency of the iron removal from ferritin.
Thus, we prepared the protein cage apoferritin using the reductive mobilisation of
Fe(III). The apoferritin cage was then studied using diverse techniques such as column
chromatography, gel electrophoresis, and mass spectrometry in order to determine the
structure of apoferritin after removal of its iron core. Also, we studied the solubilisation
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of ferritin and one of its derivatives (cationized ferritin) in organic solvents which could
potentially lead to the synthesis of quantum dots in non-aqueous media in a controlled
manner.
3.3 Results & discussion
3.3.1 Preparation of the protein cage apoferritin from horse spleen
ferritin
In our synthesis of apoferritin, we used a reductive dissolution process established by
Mann and co-workers.[334, 335] This preparation consists of 5 repetitions of a dem-
ineralization procedure: 1) ferritin protein was dialysed against NaOAc buffer at pH
5.5 for 20 min, 2) mercaptoacetic acid was added to the buffer and dialysed for 3 h, 3)
buffer was removed and ferritin was dialysed against fresh NaOAc buffer at pH 5.5 for
20 min.
The progressive release of iron was clearly seen by a decolouration of the protein so-
lution from red-brown solution for ferritin to pale yellow solution for apoferritin to
give the demetallated protein consisting of the intact polypeptide shell surrounding a
water-filled nanodimensional cage (Scheme 3.1).
Scheme 3.1: Change of colour of the protein during apoferritin synthesis.
The yellow colour of apoferritin is reported as an inherent property of the protein as-
sociated with the aromatic amino acids.[336, 337]
Figure 3.1 shows the UV-visible absorption of ferritin and apoferritin samples confirm-
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ing the release of iron:
Figure 3.1: UV-visible spectra of ferritin and apoferritin.
The absorbance spectra of ferritin and cationized ferritin shows two peaks around 280
nm and 400 nm. The first peak previously discussed corresponds to the protein moiety
(aromatic side chains and peptide bonds) and the second peak is due to the presence of
iron within the protein. As expected, the curve of the apoferritin - protein without iron
- does not show any peak around 400 nm thus confirming the release of the hydrated
iron(III) oxide core.
Sometimes, the apoferritin solution was obtained as a cloudy solution suggesting the
formation of aggregates of protein during the procedure. This could be avoided by
refreshing the dialysis buffer frequently.
3.3.2 Purification of apoferritin by gel filtration
3.3.2.1 Size exclusion chromatography (SEC) principle
SEC is a chromatographic method in which particles are separated depending on their
size or hydrodynamic volume. Particles with different sizes elute through a stationery
phase (superdex = dextran over reticulated agarose) at different rates.
The apparatus or column consists of a hollow tube packed with small polymer beads
defined to have pores of various sizes (Figure 3.2). Small particles can enter pores or
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channels present in the matrix, whereas larger ones cannot. Larger particles can not
enter the pores, and thus the larger the particles, the less overall volume to traverse
through the column, and the faster the elution.
Figure 3.2: SEC principle.
3.3.2.2 Elution profiles of ferritin and apoferritin
After filtration through a 0.20 µm filter, ferritin sample remained a red-brown solution
and apoferritin sample became a clear pale yellow solution allowing removal of large
aggregates of protein formed during iron reduction (data not shown).
Ferritin and apoferritin samples (0.25 mL of each) were loaded onto a column Superdex
75 (< 100 kDa) and the elution flow was fixed at 0.5 mL min−1. The size exclusion of
the column is such that molecules smaller than 100 kDa were retained on the matrix
and eluted last. In order to detect the protein, the absorption of the samples was
measured at 280 nm.
Figure 3.3 shows the elution profiles of ferritin and apoferritin:
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Figure 3.3: Size exclusion chromatography of ferritin and apoferritin.
The peak at V = 7 mL represents the biggest component of the two solutions which
is the 24 polypeptides structure of ferritin and apoferritin. This results suggests that
ferritin and apoferritin have a similar diameter size of 12 nm and is evidence that
apoferritin shell is not decomposed/disassembled during the removal of iron. No peak
corresponding to subunits or other proteins was found suggesting a good purity of our
samples.
For more accuracy, the residues obtained after filtration were analysed by denaturing
gel electrophoresis.
3.3.3 Assessment of apoferritin purity by denaturing gel electrophore-
sis
3.3.3.1 SDS-PAGE principle
SDS-PAGE (sodium dodecyl sulphate polyacrylamide gel electrophoresis) is a technique
used to separate proteins according to their electrophoretic mobility and their relative
molecular mass (Figure 3.4).
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Figure 3.4: SDS principle.
The matrix is made by polymerisation of a mixture of acrylamide and polyacry-
lamide where the size of the pores are generated by the amount of acrylamide. The
proteins are first concentrated on the stacking gel and then separated on the resolving
gel. Separated proteins are finally visualized by staining with Coomassie followed by
destaining with methanol/acetic acid/water.
3.3.3.2 Ferritin and apoferritin under denaturating conditions
Four samples (F1 ferritin 8.5 mg mL−1, F2 ferritin 4.25 mg mL−1, A1 apoferritin 8.5 mg
mL−1, A2 apoferritin 4.25 mg mL−1) were first mixed with SDS, an anionic detergent
that denatures secondary and non-sulphide-linked tertiary structures. The SDS binds
to the protein and applies a negative charge to the protein in an uniform proportion,
so that the distance of migration through the gel is directly related to the size of the
protein. Boiling all samples at 95 ◦C for 1 minute further denatured the proteins.
Protein samples were then deposited and submitted to an electric current causing the
negatively charged proteins to migrate from the negatively charged stacking gel to the
positively charged resolving gel. Contrary to the previous experiment of size exclusion
column, larger molecules encounter more resistance and do not migrate easily in the
gel while smaller molecules fit through the pores and travel farther down the gel.
Below is the SDS-PAGE obtained for our four samples (Figure 3.5).
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Figure 3.5: SDS-PAGE of ferritin (F1 and F2) and apoferritin (A1 and A2). The protein
marker (PM) is on the left lane.
The SDS anionic detergent causes the apoferritin to disassemble into its subunits. The
subunits could thus move through the gel matrix depending on theirs global charges
and respective molecular masses. As can be seen, only one band is visible for ferritin
and apoferritin in different concentrations corresponding to approximately 20,000 Da,
which is in agreement with the subunits molecular weight of ferritin (21,000 for H- and
19,000 for L-subunit).[335, 338]
This observation underlines the result of the size exclusion experiment i.e. our protein
is pure and does not contain significant amounts of any other protein.
Now that the purity of both the commercial protein ferritin and the protein apo-
ferritin have been studied, it is useful to know the actual amount of protein present in
solution as well as the amount of iron before and after reductive dissolution of the iron
core. This is described in the following paragraphs by conducting a bicinchoninic assay
(BCA) to detect the protein content and by mass spectrometry for the amount of iron.
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3.3.4 Determination of apoferritin purity by BCA assay
The BCA assay is a colorimetric biochemical assay for detecting the concentration of
proteins in a solution; it is based on the Biuret reaction where the peptide bonds of
proteins/polypeptides react with copper(II) under alkaline conditions producing Cu+
that complexes with bicinchoninic acid forming a purple product. The amount of
protein present in a solution can be quantified by measuring the absorption spectra at
562 nm and comparing it with protein solutions of known concentrations (bovin serum
albumin (BSA) in our case).
It is important to note that the commercial proteins that we use (ferritin and cationized
ferritin) are dissolved in 0.15 M NaCl solutions. BCA assays were undertaken by testing
the samples without and with NaCl salt.
Table 3.1 shows the results of the BCA assay realised in water:
Concentration Concentration
%
expected (mg mL−1) given by BCA assay (mg mL−1)
Ferritin
0.5 0.25 50
0.25 0.12 48
Cationized ferritin
0.5 0.043 8.6
0.25 0.015 6
Table 3.1: Results of the BCA assay for ferritin and cationized ferritin prepared in water
solutions only.
These results show that 49% of protein is present in the ferritin commercial solution
and only 7.3% in the commercial solution of cationized ferritin.
Table 3.2 allows the comparison of proteins in water only to proteins prepared in
0.15 M NaCl solutions in order to produce the same environment for the proteins than
the commercial solutions:
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Concentration Concentration
%
expected (mg mL−1) given by BCA assay (mg mL−1)
Ferritin
0.11 0.08 73
0.21 0.12 57
0.43 0.21 49
0.64 0.30 47
0.85 0.39 45
Cationized ferritin
0.07 0.035 50
0.14 0.072 51
0.28 0.133 48
0.55 0.257 47
Table 3.2: Results of the BCA assay for ferritin and cationized ferritin in NaCl solutions.
When the samples are prepared in 0.15 M NaCl solutions, a clear increase in the pro-
tein content present in the commercial solutions is observed for both of the ferritins.
Nevertheless, there is a clear diminution of the protein fraction when the concentration
of the protein is increased, this can be explained by the presence of detergents in the
samples or by a variation in the pH during the solution preparation.
Making an average of the results, we can assume that 49% of protein is present in the
commercial solution of cationized ferritin and approximately 54% in the ferritin solu-
tion. These observations are of importance in order to compare the amount of protein
to the amount of dots used during our experiments on the formation of biocompatible
composites based on QDs and apoferritin.
3.3.5 Determination of iron content by ICP-MS analysis
Inductively Coupled Plasma-Mass Spectrometer (ICP-MS) is a highly sensitive instru-
ment capable of the determination of a range of both metals and non-metals between
nanograms per litre to 100 milligrams per litre. This is based on the coupling of a
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plasma torch producing ions and a mass spectrometer for separating and detecting
ions. The sample is injected by an auto sampler, nebulized and then converted to a
plasma under high temperature (6, 000 ◦C to 8, 000 ◦C). The ions pass through different
cones and are separated depending on their atomic mass and charge.
Ferritin (85 mg mL−1) and apoferritin (8.5 mg mL−1) samples were analysed and the
presence of iron was determined (Table 3.3):
Metals (µg L−1) Mn Fe Cu Zn Se Mo Cd Pb
Diluent blank 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Control × 20,000 0.06 491.07 0.73 5.37 0.00 0.00 0.02 0.04
Test × 20,000 0.00 0.39 -0.03 -0.48 -0.02 0.01 0.00 0.00
Test × 5,000 0.00 0.33 0.03 -0.43 -0.01 -0.01 0.00 0.00
2nd Test × 5,000 0.01 0.15 0.09 -0.05 -0.02 -0.01 0.00 0.00
Table 3.3: Metals analysis present in ferritin (control sample) and apoferritin (test sample) by
ICP-MS.
In the 20,000 times diluted ferritin sample, 491.07 µg L−1 of iron were detected, which
means that 9821.4 103 µg L−1 were present before dilution in the original sample of
85 mg mL−1. Thus, in 1 mL of the commercial solution of ferritin, there is 9.82 mg of
iron that represents 11.5% of the sample. However, as shown previously, this sample
only contains 50% of ferritin, so in 1 mL of sample, there is 42.5 mg of ferritin, which
means that 23% of iron is present in the protein itself which is in agreement with the
literature.[195, 338] Following this, the calculations made for apoferritin gave 0.18%
of iron remaining after reductive dissolution of the iron core. This is lower than the
residual iron percentage (2%) previously reported by Price and Joshi as determined
using thioglycolate.[339]
3.3.6 Solubility studies of ferritin in organic solvents
As the syntheses of quantum dots in aqueous solution are more complex and less de-
veloped than in organic media, the solubilisation of horse spleen ferritin in organic
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solvents was studied by hydrophobic ion pairing (HIP) methodology and UV-visible
absorption.[340–342] The solubilisation of a commercially available solution of cation-
ized ferritin was additionally studied.
The cationization of ferritin is based on the covalent blocking of the free carboxyl groups
on the protein shell by small molecules containing a positive charge at the unattached
end (N, N -dimethyl-1, 3-propanediamine (DMPA), hexamethyldiamine (HMD)).
In Table 3.4, the distribution of the charged amino acids inside the cavity (internal
phase) and outside (external phase) of ferritin and cationized ferritin are reported:
Protein Subunit
Amino acid
K R H D E
Ferritin
H 13 8 11 14 18
interior 1 0 5 2 5
exterior 6 4 0 8 4
Cationized ferritin
H 13 8 11 6 14
interior 1 0 5 2 5
exterior 6 4 0 modified modified
Ferritin
L 9 11 6 12 15
interior 5 4 4 4 7
exterior 3 5 0 6 3
Cationized ferritin
L 9 11 6 6 12
interior 5 4 4 4 7
exterior 3 5 0 modified modified
Table 3.4: Distribution of the amino acids lysine (K), arginine (R), histidine (H), aspartic acid
(D), glutamic acid (E) in ferritin and cationized ferritin. Values were estimated using pdb files
2fha and 2fga for H and L ferritin subunits respectively from protein data bank.
Solubilisation of ferritin and cationized ferritin were realised by complexation of the
proteins to the surfactant AOT (bis(2-ethylhexyl) sulfosuccinate sodium salt) with and
without considering the purity of the proteins. Studies were made in dichloromethane,
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hexane and toluene at different concentrations of protein and at different pHs (Scheme 3.2).
Scheme 3.2: Schematic illustration of complexation process between ferritin and AOT surfac-
tant.
No transfer was observed when considering the purity calculated previously in the
commercial solutions. Results of complexation considering completely pure samples
(100% protein content) are reported in Table 3.5.
Hexane DCM
Ferritin
× ×
(ratio 1:1 to 1:5)
Cationized ferritin √ √
(ratio 1:1)
Table 3.5: Transfer of ferritin and cationized ferritin from aqueous solution to organic solution
through complexation with the surfactant AOT.
Ferritin/AOT complexation was exploited over a range of ferritin/AOT ratios from
1:1 to 1:5 in NaOAc 1 mM buffer pH 3.8 and in NaOAc 100 mM buffer pH 4.4, unfor-
tunately the increased amount of AOT surfactant did not induce any solubilization of
ferritin in organic solvents. Interestingly, different results were obtained for the cation-
ized ferritin with transfer in the organic phase for a protein concentration of 10 mg
mL−1 in 100 mM NaOAc buffer (no transfer was observed in the case of a concentra-
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tion protein of 2 mg mL−1). This phase transfer was indicated by the colour of the
sample (Table 3.6):
Hexane DCM
Before mixing
lower phase orange colourless
upper phase colourless orange
After mixing
lower phase colourless orange
upper phase orange colourless
Table 3.6: Changes of colour observed during the transfer of cationized ferritin from aqueous
solution to organic media.
The transfer of cationized ferritin could be easily seen with the naked eye as shown
in Figure 3.6:
Figure 3.6: Transfer of the cationized ferritin from the aqueous media to the organic solvent,
hexane.
Figure 3.7 shows the UV-visible absorption spectra of cationized ferritin in hexane
and DCM.
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Figure 3.7: UV-visible spectra of cationized ferritin in different organic solvents.
Because of its iron core, ferritin has a broad absorption band in the ultraviolet region
that tails into the visible region of the spectrum. The UV-visible spectra of cationized
ferritin/AOT in hexane and DCM phases show the shoulder around 280 nm of the
protein moiety[260] and clearly demonstrates the successful transfer of the cationized
ferritin protein from the aqueous phase to the DCM phase. In the case of the DCM
experiment, the UV-visible absorption spectra of the aqueous phase showed no absorp-
tion peak around 280 nm as expected, thus confirming the solubilization of cationized
ferritin in organic media.
At this stage, it is important to point out that:
• The cationized ferritin is soluble in different organic solvents, but not the ferritin.
• The commercially available cationized ferritin is relatively expensive.
For these reasons, we then undertook the synthesis of the cationized ferritin.
3.3.7 Preparation of the cationized ferritin
Cationized ferritin was obtained by the activation of carboxyl groups of ferritin with a
water-soluble carbodiimide, 1-ethyl-3(3-dimethylaminopropyl)carbodiimide hydrochlo-
ride (EDC) followed by the subsequent reaction of the activated carboxyls with an
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amine of the general type RNH2 such as N, N -dimethyl-1, 3-propanediamine (DMPA)
giving tertiary amine derivatives or, hexamethyldiamine (HMD) giving primary amine
derivatives (Scheme 3.3).[343]
Scheme 3.3: Mechanism of activation of carboxyl groups by EDC and further reaction with
amines resulting in the amide bond formation.
Both of these amines were used in the reaction at pH 6.5 (i. e. with apoferritin assem-
bled) giving cationization of the external Asp and Glu amino acid only as transparent
orange solutions.
The modification of protein carboxyls by such a procedure causes a change in charge
of two units per modified carboxyl group from -1 to +1: the overall pI of the molecule
changes from 4.5 for the ferritin[344] to higher values depending on the degree of cation-
ization of the carboxyl groups.
The degree of cationization can then be resolved by determining the number of -NH2
amine groups formed. There are several methods for the measurement of amine groups
in proteins and other molecules using commercially available reagents such as TNBS
(trinitrobenzene sulfonic acid) or OPA (o-phthaldialdehyde).[345, 347] In our case, we
detected amine groups with TNBS reagent that is simpler to use. Ferritin containing
primary amines can react with the TNBS (extinction coefficient 14,400 cm−1) to form
a highly chromogenic derivative (Scheme 3.4).
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Scheme 3.4: Mechanism of the free NH2 of the cationized ferritin with an amine detection
reagent.
The amine content of the compound was then determined by measuring the absorbance
of the orange-coloured product at 335 nm by comparison to a standard curve generated
by use of an amine-containing compound, the alanine (Figure 3.8).
Figure 3.8: UV-visible of the cationized ferritin before and after blocking of the -NH2 groups
by TNBS.
After calculations, we found that 25% of the amino groups remain free and this result
is in good agreement with the data reported in the literature.[209]
It is interesting to note that the successful cationization of the commercially available
ferritin could be applied to the apoferritin as the structure of the protein shell is con-
served during the preparation of the protein cage as described in section 3.3.1.
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3.4 Conclusion
The protein cage apoferritin has been prepared from ferritin by reductive mobilisation
of its iron(III) core. We have showed that apoferritin has been efficiently freed from
its ferryhydrite core with only 0.18% of iron remaining. Furthermore, apoferritin and
ferritin showed the same elution profile by size exclusion chromatography and the same
characteristic bands of the subunits around 20 kDa after denaturation with SDS, leading
to the conclusion that the structure of the apoferritin has been conserved along the
removal of the iron core. The transfer of cationized ferritin in organic solvents leads
to the potential of cationizing ferritin and apoferritin in order to synthesize quantum
dots in a controlled manner in non-aqueous media.
Chapter 4
PbS-apoferritin composites
4.1 Introduction
This chapter describes the synthesis of a biocompatible aqueous NIR fluorescent label
based on a PbS QD entrapped in the hollow core of a horse spleen apoferritin (AFt)
protein cage.[346] As mentionned in the chapter 1, section 1.3.1, only CdSe, ZnSe and
CdS nanoparticles have been entrapped within the apoferritin cavity by the entrance of
Cd, Zn, Se and S precursors through the protein channels, but no luminescence studies
have been reported on the composites formed.
4.2 Objectives
The hollow core of the apoferritin protein limits the size of the encapsulated QD to ∼
8 nm and provides an exterior protein coat to the QD that allows covalent attachment
of other biomolecules, such as oligosaccharides, peptides and fatty acids, using well
established chemical techniques.[347]. In addition, this composite provides an efficient
fluorescent label in the NIR. Therefore, it could provide an attractive system for bio-
logical and medical studies.
In this chapter we investigated two routes of synthesising the AFt-PbS composite:
• The first route involves disassembly of the apoferritin shell into its component
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protein subunits, and then reassembly of the protein shell in the presence of pre-formed
PbS QDs, see Scheme 4.1. As mentioned previously, to our knowledge, this method
has never been used to ‘trap’ quantum dots.
Scheme 4.1: Encapsulation of PbS QDs within the cavity of apoferritin by the disassem-
bly/reassembly process.
• In the second route the apoferritin is used as a ‘nanoreactor’ to promote the
formation of the dots from their precursors, see Scheme 4.2.
Scheme 4.2: Encapsulation of PbS QDs within the cavity of apoferritin either by entrance of
ions through the channels.
4.3 Results & discussion
For the reassembly route, disassembled apoferritin in 0.1 M NaCl adjusted to pH = 2.0
with 2 M HCl(aq.) was added slowly to the preformed PbS quantum dots in deionized
water. PbS dots were synthesized as described in chapter 2 and were used as a solution
of pH 9.0. The pH of the PbS solution was high enough (∼ 9.0) to induce the reassembly
of the apoferritin subunits around the dots without further addition of base.
For the nanoreactor route, Pb(CH3COO)2 and Na2S were injected in deionized water
to apoferritin in 0.1 M NaOAc buffer at pH = 5.5.
In both routes, the colour of the AFt-PbS composites solutions varied from pale brown
for the lowest Pb/S molar ratio 1:0.3 to black solutions for the highest Pb/S MR 1:0.7.
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Furthermore, apoferritin-PbS composites seemed to be sensitive to storage conditions
in that the composites were stable when kept under nitrogen in the dark at 4 ◦C, but
decomposed quickly when exposed to light and air at RT.[346]
4.3.1 Structural study of the PbS-apoferritin composites
The solutions were examined several times over a period of 3 months by photolumines-
cence (PL) spectroscopy. For PL experiments, the AFt-PbS composites were studied
as liquid solutions in a glass vial or deposited on a glass substrate.
Figure 4.1 shows AFM images of AFt, PbS QDs and AFt-PbS composites prepared
by the reassembly route.[346]
Figure 4.1: AFM images of PbS QDs (Pb/S MR = 1:0.3), AFt and AFt-PbS composites and
their correspoding size distributions. This work was realised in collaboration with L. Turyanska
from the Physics Department of Nottingham University.
Preliminary AFM studies of the PbS QDs indicate that the dots had spherical shape
with average height, d, increasing from 3 to 12 nm for Pb/S molar ratio increasing from
1:0.3 to 1:0.7.[302] Here we focus on PbS MR 1:0.3 and average height d = 5 ± 2 nm.
The size of the AFt-PbS composite indicated by our AFM studies is i.e. d = 9 ± 5
nm, a value close to that measured for our apoferritin (d = 9 ± 4 nm), but smaller
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than that expected for the external shell of ferritin and apoferritin (d = 12 nm). This
discrepancy is thought to be caused by the compression of the apoferritin shell induced
by the AFM-tip, an effect also observed by other groups for ferritin.[348]
To reveal the morphology and structure of our AFt-PbS composite, we have per-
formed TEM experiments (Figure 4.2).[346]
Figure 4.2: (a) TEM image of unstained AFt-PbS (PbS MR = 1:0.3) composites synthesized
using the ‘nanoreactor’ route. (b-c) TEM images of AFt-PbS (PbS MR = 1:0.3) composites
stained with uranyl acetate and synthesized using the ‘nanoreactor’ (b) and reassembly (c)
routes. (d) EDX spectra of stained AFt-PbS (PbS MR = 1:0.3) composites. The U- and
Cu- lines arise from the uranyl acetate stain and TEM grid, respectively. The inset in part
(a) shows the HRTEM image and X-ray diffraction (XRD) pattern for unstained AFt-PbS
composites synthesised using the reassembly route. These analyses of our Aft-PbS composites
were produced by Dr. M. Li and Prof. S. Mann from the University of Bristol and Dr. T. Ben,
A. Beltra´n and Prof. S. Molina from Ca´diz Universidad in Spain.[346]
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Initially, the contrast in the TEM image of Figure 4.2a is completely dominated by the
PbS core of the composite. However, the rather weaker contrast of the protein shell
can be clearly revealed when the composites are negatively stained with uranyl acetate
(Figure 4.2b-c). The TEM images of Figure 4.2b-c show AFt-PbS composites made of
an intense central core and a lighter shell. From the analysis of the TEM images of
Figure 4.2b-c, we find that the diameter of the composite is d = 13 ± 1 nm, which is
consistent with the value expected for apoferritin (d = 12 nm).
Energy Dispersive X-ray (EDX= spectra for stained and unstained samples (Figure 4.2d)
also reveal characteristic Pb- and S-lines, thus supporting the presence of PbS core in-
side of the apoferritin as well as the presence of cysteine and methionine residues in
the protein shell.
To reveal the crystal structure of the core inside the AFt-PbS composite, we have
examined Selected Area Electron Diffraction (SAED) pattern and High Resolution
TEM (HRTEM) images with the help of Dr. T. Ben, A. Beltra´n and Prof. S. Molina
from Ca´diz Universidad in Spain. The SAED pattern in the inset of Figure 4.2a displays
peaks corresponding to interplanar distances of 1.31 ± 0.02 A˚ and 2.09 ± 0.01 A˚,
characteristic of the (420) (1.327 A˚) and (220) (2.098 A˚) planes of bulk PbS.[27] Analysis
of HRTEM images for 35 particles also indicate that the PbS core has an average
diameter d = 6 ± 2 nm. This estimate is close to the size of the PbS QDs (without
apoferritin) derived from our AFM (d = 5 ± 2 nm) and HRTEM (d = 6 ± 2 nm)
experiments.[346]
As further proof of the incorporation of PbS in apoferritin, we have examined High
Angle Annular Dark Field (HAADF) (Figure 4.3b) and Electron Energy Loss (EEL)
spectra (Figure 4.3c) taken with a Scanning TEM (STEM) microscope. This is a well-
suited technique to investigate the chemical composition of nanostructures[349, 350] and
does not require the use of staining agents as the contrast in the image is determined
by the atomic number of the constituting elements.
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Figure 4.3: (a) HRTEM images and (c) spatial sequence of EELS spectra for AFt-PbS com-
posites synthesized using the nanoreactor route. The spectra were recorded with an acquisition
time of 1 s and show the characteristic signals of S-L (∼ 165 eV), C-K (∼ 285 eV) and N-K (∼
401 eV) edges. The inset shows the HAADF image for one composite. Each EEL spectrum was
taken at a particular x-position along the arrow crossing the composite in the HAADF image.
(b) STEM-HAADF image of unstained AFt-PbS composites synthesized using the reassembly
route.[346]
The HAADF-STEM image in Figure 4.3b reveals composites made of a lighter shell
surrounding a brighter core, which supports the shell-core structure of the AFt-PbS
composite.
Figure 4.3c presents a sequence of EEL spectra, each taken at a particular position
along the line crossing the circular particle marked in the inset of Figure 4.3c by an
arrow. The EEL spectra indicate that the outer layer of the composite contains N-,
C- and S-atoms as expected for the shell of AFt, while a larger number of S-atoms is
revealed in the particle core as expected for PbS.
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4.3.2 Optical properties of the PbS-apoferritin composites
Figure 4.4 shows the room temperature PL spectra of representative PbS QDs (Pb/S
MR = 1:0.3) and AFt-PbS composites prepared by the ‘nanoreactor’ and reassembly
routes. The PbS and AFt-PbS composites provide efficient and stable photolumi-
nescence in the NIR spectral region of the electromagnetic spectrum. However the
encapsulation of the PbS dots in apoferritin tends to shift slightly the PL emission to
higher energy values.[346]
Figure 4.4: Room temperature PL spectra of PbS QDs (Pb/S MR = 1:0.3) and AFt-PbS
composites. ∆E is the energy shift of the PL emission of the AFt-PbS solution relative to that
of PbS QDs.[346] This work was realised in collaboration with L. Turyanska from the Physics
Department of Nottingham University.
The small energy shift, ∆E, is similar for the two encapsulation methods and suggests
that apoferritin acts to limit the size of the encapsulated dot. In turn this would
prevent Ostwald ripening and coalescence of the dots thus leading to smaller dots and
corresponding higher emission energies.
The value of ∆E is different for AFt-PbS solutions based on dots with different average
diameter d. It tends to be larger in dots with higher energy and smaller values of d
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and changes its sign when d becomes larger (d ∼ 10 nm) than the diameter of the
apoferritin core (d = 8 nm) as shown in Figure 4.5.
Figure 4.5: Dependence of ∆E on the peak energy of the QD PL emission. The value of ∆E
is derived by comparing the PL spectra of PbS QDs and of AFt-PbS composites synthesized
using the reassembly route. The grey area indicates dots with average size d < 10 nm.[346]
This shift is also observed when comparing the PL spectra of the different particles
resulting from the centrifugation of the AFt-PbS solution. Centrifugation on the AFt-
PbS composite solution causes a partial phase separation into a light brown upper
solution and a dark brown lower solution (not a solid precipitate) with an ill-defined
interface. The AFt-PbS composite, which tends to concentrate in the lower phase, was
carefully removed using a syringe and deposited on a glass substrate for PL studies. As
shown in Figure 4.6, the emission energy of the lower phase is very similar to that of
the original AFt-PbS solution, while that of the remaining solution is shifted to lower
energy and coincides with that of PbS dots formed in the absence of apoferritin.[346]
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Figure 4.6: RT PL spectra for the AFt-PbS solutions with and without centrifugation.[346]
The intensities of the PL emissions from the PbS QDs and AFt-PbS composites
are comparable and found to be stable over a period of at least 3 months. The stable
and efficient PL signal of the AFt-PbS composites allowed us to study their optical
properties over a wide range of temperatures from 4 K to room temperature, and of
excitation powers, P (10−3-10 W cm−2). For the temperature study, the as-prepared
sample was dried on a glass substrate. As shown in Figure 4.7, with increasing T from
4 to 292 K, the peak energy, E, of the PL spectrum for the AFt-PbS composites blue-
shifts and its T -dependence for T > 150 K can be described by the coefficient α = 0.3
meV K−1 as expected for PbS QDs.[302, 346]
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Figure 4.7: PL spectra of AFt-PbS composites at various T and excitation power P = 0.2 W
cm−2. This work was realised in collaboration with L. Turyanska from the Physics Department
of Nottingham University.
Also, the peak intensity of the PL emission decreases monotonically by less than a
factor 10; this high thermal stability of the PL intensity indicates strong carrier con-
finement in the QD and a relatively low density of non-radiative recombination centres
in the AFt-PbS composite.
4.3.3 Native gel electrophoresis of PbS-apoferritin composites
The effectiveness of the reassembly route employed for the synthesis of our AFt-PbS
composites was tested by native polyacrylamide gel electrophoresis (PAGE). Proteins
are not denatured and therefore they are separated based on their charge-to-mass ratio.
Figure 4.8 shows the native PAGE of AFt-PbS composites in comparison to ferritin
and apoferritin.
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Figure 4.8: A. Native PAGE of 1) apoferritin 8.5 mg mL−1, 2) apoferritin 0.85 mg mL−1,
3) ferritin 8.5 mg mL−1, 4) ferritin 0.85 mg mL−1, 5) and 6) AFt-PbS synthesised by the
reassembly route. The protein marker is on the left lane. B. Native PAGE of reconstituted
ferritin stained for the protein (a) and iron (b) (adapted from reference [351], no protein marker).
Bryce and Crichton analysed reconstituted ferritin (addition of ferrous ammonium
sulphate to a solution of apoferritin in imidazole buffer pH 7.45 plus oxidants) by poly-
acrylamide gel electrophoresis (6.5% gels in buffer at pH 8.6).[351] By using the amido
black and potassium ferrocyanide dyes to stain the protein and the iron, respectively,
they showed that apoferritin and iron migrated together over the gel as seen in Fig-
ure 4.8B. After runing our different samples on a 10% native gel (Figure 4.8A), we
observed that staining revealed two bands for each sample which were also seen for the
reconstituted ferritin and correspond to apoferritin monomer (at 480 kDa) and dimer
(the latter is visible on an enlarged image).[225] As Bryce et al. also showed that horse
spleen apoferritin and horse spleen ferritin migrate at the same level[203], we affirm
that the encapsulation of PbS QDs using the disassembly/reassembly route does not
influence the external electrostatic potential of the protein shell. Furthermore, PbS
QDs did not migrate, remaining in the stacking gel (data not shown) and no accumu-
lation of dots was observed for AFt-PbS composites, which implies that PbS QDs are
encapsulated within the apoferritin cage.
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4.4 Conclusion
We have exploited both the self-assembly and nanoreactor properties of apoferritin to
incorporate PbS quantum dots in the apoferritin cavity. Apoferritin-PbS composites
have been prepared in aqueous solution with photoluminescence emission in the wave-
length region (∼ 1,000 nm) of interest for studies of biological media. We have proved
by several spectroscopic techniques that AFt-PbS composites are made of PbS cores
surrounded by the apoferritin shell. Furthermore, it is the first time that the disassem-
bly/reassembly route has been employed for the encapsulation of quantum dots within
the apoferritin cage. The efficiency of this technique has been confirmed by native
gel electrophoresis showing that the external surface of the protein is conserved and
quantum dots do not bind on the outer surface of apoferritin.
Chapter 5
Bioluminescence resonance
energy transfer (BRET) with
PbS quantum dots
5.1 Introduction
5.1.1 Introduction to FRET phenomena
Fluorescence (or Fo¨rster) resonance energy transfer (FRET) is a powerful spectroscopic
technique that occurs whenever the emission spectrum of an excited fluorophore (called
donor D) overlaps with the absorption spectrum of a neighbouring molecule (called
acceptor A).[352] FRET measures small variations in the separation distance between
D and A coupled by a dipole-dipole interaction. This sensitive technique allows the
detection of molecular interactions and conformational changes.[82, 353–356]
The principle of this method can be explained as following:
D
photon excitation−−−−−−−−−−−→ D∗ +A energy transfer−−−−−−−−−→ D+A∗ fluorescence−−−−−−−→ A
In the first step, a fluorescent donor molecule D is excited by the normal absorption of
a photon and transfers this excitation energy to an acceptor molecule A in the second
CHAPTER 5. Bioluminescence resonance energy transfer (BRET) with PbS quantum
dots 86
step. At this stage, the energy transfer is a non-radiative transition (interaction of the
transition dipoles of D and A, it does not occur via emission of a photon from D∗ and
reabsorption by A). Finally, A may lose its excess energy by fluorescence. As a result
of FRET, a quenching of the fluorescence of D and an enhancement of fluorescence
of A can be observed. The efficiency of FRET increases as the overlap between the
emission of D and the absorption of A increases. FRET is only significant if the donor
and acceptor groups are part of the same molecule or hold on close molecule complex.
The efficiency E is described by the equation (5.1):
E =
R0
6
R0
6 + r6
(5.1)
where r is the distance between D and A and R0 is the Fo¨rster distance at which
half the D molecules participate in the FRET and half decay by the usual radiative
and non-radiative processes (transfer rate equal to the decay rate of the donors in the
absence of the acceptors). The Fo¨rster distance R0 is dependent on individual D and
A pairs typically 10-100 A˚.
Oligomers (peptides, nucleic acids) of different lengths and steroids have been em-
ployed as spacers between D and A to demonstrate that greater separation leads to less
efficient energy transfer.[357]
Semiconductor nanoparticles have been employed in a wide range of FRET appli-
cations as both donor and acceptor roles. QDs have proved their ability to be used as
efficient donors whereas their use as energy acceptors is still uncertain.[358–361]
During FRET experiments, some rules apply:
• Increasing the number of energy acceptors per QD, increases FRET quenching
efficiency,
• Increasing Fo¨rster radius, R0, increases constraints of FRET quenching. The size
of QDs can be a limitation of using dots as donors for FRET compared to organic dyes
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In experiments where the dots are used as donors due to their broad absorbance, the
energy acceptors are organic fluorophores (such as BIPS (1′-3-dihydro-1′-(2-carboxyethyl)-
3,3-dimethyl-6-nitrospiro-[2H-1-benzopyran-2,2′-(2H)-indoline]),[362] β-cyclodextrin [363],
cysteine[363–366], rhodamine[367]) and non fluorescent dyes or quenchers (QSY9, BHQ-
10, DABCYL (4-(dimethylaminoazo)benzene-4-carboxylic acid), squaraine)[368–370].
The general idea of these experiments is described in Scheme 5.1:
Scheme 5.1: One-step FRET mechanism with a QD as a donor and α-cyclodextrin-QSY-9 as
an acceptor (adapted from reference [363]).
β-cyclodextrin-QSY-9 used as a dye conjugate binds to the MBP domain and this
assembly results in FRET quenching: the energy of the excited dot is adsorbed by the
organic dye. When maltose is added to this system, the quencher is displaced and the
QD photoluminescence is restored.
To accomplish FRET over long distances, multistep energy transfer processes have
been described (Scheme 5.2).[363, 371]
Scheme 5.2: Two-step FRET mechanism (adapted from reference [363]).
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Multiplexed FRET can be realised with two configurations: A) a single colour QD
can interact with multiple distinct acceptors and B) multiple donor populations can
interact with one type of acceptor (Scheme 5.3).[372]
Scheme 5.3: Schematic representation of the FRET multiplexing configurations (adapted from
reference [372]).
Moreover, some groups reported the application of FRET between II-VI QDs and
fluorescent dyes linked together by different biomolecules such as antibody,[369, 373,
378] BSA,[374, 377] peptide,[367, 375, 376, 382, 383] and DNA[379–381].
CdTe nanoparticles (NPs) of different sizes were used as energy donors and accep-
tors in antigen/antibody immunocomplexes. The luminescence of green-emitting QDs
(λmax = 555 nm) was quenched whereas the emission of red-emitting QDs (λmax = 610
nm) was enhanced.[373]
CdTe NPs conjugated to bovin serum albumin (BSA) through a glutaric dialdehyde
cross-linker showed an increase in their emission attributed to an energy transfer from
the tryptophan moieties of albumin to the NPs.[374]
More recently, QDs have been employed as energy donors and gold nanoparticles
as acceptors. The QD luminescence was reduced by 71% due to their conjugation to
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the gold NPs. After collagenase exposure, the peptidic linkage is cleaved and emission
of luminescence from QDs is restored.[375, 376] Also, in such a system, rhodamine acts
as an efficient energy acceptor.[367]
Van Orden et al. established a FRET transfer using CdSe/ZnS quantum dots as
energy donors and tetramethylrhodamine (TMR) as dye acceptor.[377] Biotinylated
BSA conjugated to QDs were bound to streptavidin-labelled TMR. An enhancement
of the dye fluorescence was observed while the emission from the CdSe/ZnS NCs was
quenched.
The antibody/antigen interaction has proved to be an efficient system for FRET
between CdSe/ZnS core-shell NCs as donors and the ‘black hole’ quencher BHQ-10.[378]
The hybrid sensor consisted of anti-trinitrotoluene (TNT) antibody attached to the QDs
by metal affinity coordination through the histidine tail of the antibody and a dye-
labelled TNT analogue. The addition of TNT replaced the quencher-labelled analogue,
restoring the luminescence of the NCs.
Thrombin activity has been detected by a similar method where CdSe/ZnS QDs
were conjugated with an anti-thrombin aptamer itself conjugated to a DABCYL quench-
er.[369]
Willner et al. reported a FRET in CdSe/ZnS-DNA conjugates.[379, 380] Thiolated
DNA-functionalised QDs were hybridized with the complementary DNA-functionalized
Texas-Red. An energy transfer was observed from the QD to the dye. The addition of a
cleaving reagent, DNase I, resulted in a photoluminescence recovery of the nanocrystals.
A sandwich assay of DNA target has been established by Wang and co-workers.[381]
The nanosensor consisted of two oligonucleotide probes, one reporter probe labelled
with the fluorophore Cy5 as acceptor and one capture probe labelled with biotin and
conjugated to streptavidin-derivatized CdSe/ZnS QDs. Thus, the desired DNA target
is sandwiched between the two probes.
Recently, an amino-terminated histidine modular peptide was used as a linker be-
tween CdSe/ZnS NCs and a dye to show the effective proteolytic activity of proteases
such as collagenase, caspase-1, thrombin and chymotrypsin which were able to cleave
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the peptide linker.[382, 383]
5.1.2 PbS as energy acceptors in a BRET process
The BRET (Bioluminescence Resonance Energy Transfer) process is similar to the
FRET process discussed in the introduction. Nevertheless, an important limitation of
FRET is the requirement for external illumination to initiate the fluorescence trans-
fer, which can lead to background noise due to direct excitation of the acceptor. To
overcome this difficulty, the technique of BRET using a self-illuminating system has
been developed.[384, 385] Bioluminescence is an enzyme-catalysed reaction involving
the enzyme luciferase, the most well known being firefly luciferase from the firefly Phot-
inus pyralis.[386] The luciferase catalyzes the conversion of D-luciferin (substrate) to
a luciferyladenylate intermediate using ATP (adenosine 5’-triphosphate). Then, the
latter is oxidized by molecular oxygen. This gives rise to an excited oxyluciferin via a
dioxetanone intermediate. The light is emitted when oxyluciferin falls from the excited
state to the ground state (Scheme 5.4).
Scheme 5.4: Bioluminescence reaction involving the enzyme luciferase and the substrate lu-
ciferin.
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A derivative of Renilla luciferase, Luc8, was used as an energy donor in a BRET
system with commercial CdSe/ZnS quantum dots.[387, 388] Luc8 was attached to acid-
capped QDs through a peptide bond. The bioluminescence of Luc8 was decreased and
the luminescence of the QDs increased. Once the peptide bond was cleaved, biolumi-
nescence from Luc8 was recovered and the QDs emission was negated.
5.2 Objectives
The objective was to create an energy transfer from the luciferin to the PbS quantum
dots via the luciferin/luciferase system. The experiment was realised following the
bioluminescence conditions reported by Nakatsu et al. with the luciferase and luciferin
from Luciola mingrelica and ATP ratios of approximately 1:0.0022:5.3.[389]
5.3 Results & discussion
PbS dots MR 1:0.3 were capped with lipoic acid, substituting dithioglycerol which
was used as a capping agent in the previous syntheses. Lipoic acid and dithioglycerol
have a similar structure with two thiol groups that increase ligand binding to the dot
surface. Photoluminescence analyses under an Ar+ laser with an excitation wavelength
at 514.5 nm indicated a higher emission wavelength (∼ 1,220 nm) of the acid-capped
dots compared with thiol capped-PbS QDs, which can be due to the effect of capping
as AFM images from the acid-capped QDs reveal a similar diameter (d = 3-5 nm) to
the thiol-capped QD.
The BRET system was realised by activating the lipoic acid capped-PbS MR
1:0.3 by the coupling agent EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hy-
drochloride) in order to create a linkage with the enzyme luciferase through an amide
bond (Scheme 5.5).
CHAPTER 5. Bioluminescence resonance energy transfer (BRET) with PbS quantum
dots 92
Scheme 5.5: Coupling of dihydrolipoic acid-capped PbS QDs with luciferase using EDC cou-
pling agent and bioluminescence energy transfer from the luciferin excited state to the PbS
dots.
Thus the luciferase would be covalently attached to the PbS QD surface, additionally
the close proximity of the enzyme and the substrate should allow energy transfer. Lu-
ciferin and ATP were then successively added to initiate the reaction. Bioluminescence
from luciferin and photoluminescence from PbS QDs were measured separately using
a 250-800 nm/900-1,400 nm range detector, respectively, see (Figure 5.1).
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Figure 5.1: Bioluminescence and photoluminescence intensities of D-luciferin/luciferase and
PbS dots respectively before (black lines) and after (red lines) coupling reaction.
The PL emission from PbS QDs was detected with an InGaAs detector in a dark
room in order to minimize a possible direct excitation of the quantum dots by any
source of light. With an integration time of 60 s and despite a low intensity, a PL
emission from the PbS dots could be observed at 1,142 nm whereas the emission of the
luciferase (λem = 490 nm) and D-luciferin (λem = 550 nm) decreased when subject to
the proximity of PbS dots.
Repetition of such experiment was problematic due to D-luciferin being stable in Tris-
Acetate only for a short period of time of 8 to 24 h while the BRET measurement takes
∼ 10 h.
Also, So et al. reported that the binding of polymer coated-CdSe/ZnS with wild-
type firefly luciferase from Renilla reniformis (sea firefly) was unsuccessful. The use of
luciferase mutant could allow more stable conjugates.[390, 391]
5.4 Conclusion
We obtained emission from PbS quantum dots where the system D-luciferin/luciferase
from L. mingrelica acts as an energy donor and PbS quantum dots act as energy
acceptors through a bioluminescence resonance energy transfer. Luciferase, the enzyme
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catalysing the reaction, was covalently attached to acid-capped PbS QDs. The addition
of D-luciferin to the medium led to a transfer of energy from the D-luciferin to the
PbS dots. As expected, the emission of PbS QDs was observed while the emission
from D-luciferin/luciferase decreased. This successful transfer of energy makes these
nanoparticles promising tools for in vivo biomedical imaging. A similar energy transfer
could be achieved using our AFt-PbS bioconjugate system where the apoferritin protein
shell surrounding the QDs would offer a greater binding to biomolecules for labelling
experiments.
Chapter 6
Incorporation of un-natural
amino acids into human
apoferritin
6.1 Introduction
Through the past decade, the engineering of the genetic code with new functionalities
(halogeno, keto, cyano, azido, nitroso, silyl, alkene and alkyne groups) has developed as
an emerging research field with the use of non-canonical or non-coded amino acids.[392–
396]
Non-canonical amino acids such as photoactivable amino acids, isotopically labelled
amino acids, and amino acids bearing biophysical probes have been incorporated in
order to improve the study of protein structure-function relationships and to generate
proteins with novel properties.
In this chapter, our studies on the expression of human H and human L apoferritin
proteins are described followed by the incorporation of un-natural amino acids into
these proteins. The purpose of this research is to render the apoferritin shell easier
to specifically attach to other biomolecules in order to use our PbS-encapsulated apo-
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ferritin conjugates as labels for imaging. Thus, it is interesting to incorporate amino
acid analogues with new functionalities such as azido or alkyne groups which have been
reported to react specifically with alkyne and azido reagents respectively (‘click’ or
bio-orthogonal chemistry) through an Huisgen cycloaddition reaction.
6.1.1 Introduction to protein bio-synthesis
Protein biosynthesis is a two-step process involving transcription of double-stranded
deoxyribonucleic acid (DNA) into messenger RNA (mRNA) followed by translation of
the mRNA into a protein biopolymer (Figure 6.1).
Figure 6.1: Representation of DNA transcription and RNA translation during protein bio-
synthesis.
During transcription as shown in Figure 6.1b, the four 2′-deoxy nucleotides of the
DNA (guanine, cytosine, thymine and adenine) are replaced by their complementary
nucleotides, respectively cytosine, guanine, adenine and uracil.
During translation as shown in Figure 6.1c, the mRNA codons (triplets of nucleotides)
are ‘translated’ by tRNA on ribosomes into amino acids through a codon/anticodon
recognition. Each codon codes for a specific amino acid. The transfer RNA (tRNA)
plays the role of an adaptor between the amino acid and mRNA molecules showing
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high substrate (amino acid) specificity.
Thus, the requirement for a non-canonical amino acid or analogue to be incorporated
into the protein sequence is that its shape and size have to be similar to those of the
natural amino acid to prevent interferences with the folding of the protein.
Two approaches are available to expand the protein synthesis with non-canonical
amino acids:
• Site-directed mutagenesis. Mutagenesis is a biological technique based on the
substitution of a specific amino acid by one of the other nineteen common amino acids
given by the genetic code. For the incorporation of non-canonical amino acid, this
technique is a variation of conventional site-directed mutagenesis whose details will be
discussed below.
• Use of an amino acid auxotroph: culture medium lacking a defined natural amino
acid.
Both of these techniques require: 1) an un-natural amino acid of interest, and
2) a translation system containing ribosomes. The differences between site-directed
mutagenesis and auxotroph strains is the codon/anticodon recognition event. In the
case of mutagenesis, the suppressor tRNA must be charged with the un-natural amino
acid of interest and contain an anticodon recognizing a non-sense or terminal codon in
the DNA strand.[397, 398] Here, the non-canonical amino acid would be incorporated
as a 21st amino acid in the RNA strand. In the auxotroph method, the tRNA con-
tains an anticodon recognizing a natural amino acid which is depleted in the culture
medium, thus the non-canonical amino acid acts as a replacement for the canonical
amino acid.[399–407]
6.1.2 Previous incorporation of un-natural amino acids into proteins.
The first incorporation of a methionine analogue was reported in 1957 by Cowie and
Cohen who replaced sulphur-containing methionine (Met) by selenium-containing me-
thionine (SeMet) using the Met-auxotroph E. coli ML304d strain.[408] They observed
slower growth rate of the culture when the growth medium was supplemented with
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SeMet instead of Met.
Almost 40 years later, Kothakota, Tirrell et al. realised the incorporation of a
phenylalanine (Phe) analogue into a protein of sequence -[(GlyAla)3X]13- where X is
the analogue or the natural Phe. The plasmid encoding the protein was incorporated
into phenylalanine auxotroph cells AFpLysS and expressed in M9 medium containing
the 20 natural L-amino acids. After 10 min of induction with IPTG (isopropyl β-
D-thiogalactopyranoside), cells were sedimented and washed with M9 medium only.
Cell pellets were resuspended into M9 containing the Phe analogue and the 19 other
natural amino acids. Phe analogue incorporation was observed by UV spectra and
NMR analysis to an extent of 90% of natural Phe substituted.[399]
Following this procedure, Tirrell’s group expressed the mouse dihydrofolate reduc-
tase (DHFR) protein incorporating methionine analogues using the methionine aux-
otroph CAG18491 (Figure 6.2).[400, 401, 403–405] Also, a leucine auxotroph has been
used to incorporate a fluorinated leucine analogue into the leucine zipper protein.[406]
Figure 6.2: Methionine analogues incorporated into proteins.[400, 401, 403–405]
6.2 Objectives
To further improve the potential use of AFt-PbS composites in bio-labelling or bio-
imaging applications, we aimed to improve the binding of our composite to biomolecules
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by modifying the structure of amino acids of the apoferritin cage. Thus, the goal was to
introduce new functionalities (azido and alkyne groups) into human apoferritin through
the incorporation of un-natural amino acids. The protein cage thus modified could be
easily linked to other molecules through basic organic reactions.
6.3 Results & discussion
6.3.1 H-human and L-human apoferritin expressions
Over-expression conditions were first studied for the synthesis of H and L human apo-
ferritins. The DNA coding for these two proteins were incorporated into the plasmids
pET-11a (rHuHFt) and pET-26b(+) (rHuLFt) constructed and kindly provided by
Steven Aust (Utah State University, USA), see Figure 6.3.[409]
Figure 6.3: Plasmids pET-11a and pET-26b(+) for the expression of H and L human apofer-
ritin respectively.
Both vectors contain NdeI and BamHI restriction enzymes. The pET-11a plasmid
possesses genes resistant to chloramphenicol (Chl) and ampicillin (Amp) antibiotics
whereas pET-26b(+) possesses genes resistant chloramphenicol and kanamycin (Kan)
antibiotics.
Cell cultures growth of pET-11a and pET-26b(+). H and L human apofer-
ritins were grown following the procedure developed by Grace et al. for the coex-
pression of human apoferritin heteropolymer.[409] Both vectors were transformed into
B834(DE3)pLysS competent cells by heat shock. The respective antibiotics were added
to LB (Lysogeny broth also known as Luria broth or Luria-Bertani broth) plates over
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which cells are grown overnight at 37 ◦C. LB is a medium nutritionally rich used for
the growth of bacteria.
Positive transformants (a single colony) were grown in LB medium containing
the antibiotics chloramphenicol and ampicillin for H apoferritin expression or chlo-
ramphenicol and kanamycin for L apoferritin expression. The cultures were subse-
quently used to inoculate a large volume of M9 minimum salts medium at pH 7.0.
In order to produce higher growth rate, the M9 medium was supplemented with glu-
cose (20%), salts (CaCl2 (0.1 mM), ZnSO4
.7H2O (8.0 µM), MnSO4
.7H2O (10.0 µM),
MgSO4
.7H2O (1.0 mM), CuSO4 (2.0 µM), CoSO4
.7H2O (2.0 µM), H3BO3 (1.0 µM),
Na2MoO4
.2H2O (1.0 µM), thiamine-HCl (0.3 nM), and amino acids (L-arginine hy-
drochloride, L-histidine hydrochloride, L-isoleucine, L-leucine, L-lysine hydrochloride,
L-phenylalanine, L-threonine, L-tryptophan, L-valine) at 120 mg mL−1.
The growth of the bacterial cultures were monitored spectrophotometrically at 610
nm by measuring the optical density (OD). An absorbance unit or OD unit is directly
proportional to the concentration of the solute.[410] When OD600 reaches a value of
0.4, stimulation of protein synthesis was induced by the addition of IPTG at a final
concentration of 0.75 mM. The protein synthesis is regulated by the presence of a lac
repressor which binds tightly (dissociation constant Kd = 10
−6 M) to a DNA sequence
downstream of the T7 promoter thus inhibiting any protein synthesis. When added,
IPTG binds to the repressor with more affinity (Kd = 10
−13 M) causing it to dissociate
from the DNA and allows the mRNA for the protein of interest to be synthesised.
Purification of H human apoferritin. Cell pellets were resuspended in Tris-HCl
buffer with DNase I, RNase and lysozyme in order to remove any contamination from
DNA (e.g. plasmid), RNA and cells.
Deoxyribonuclease I (DNase I) is an enzyme catalysing the hydrolytic cleavage of
phosphodiester linkage in the DNA backbone. Cleavage preferentially occurs adjacent
to pyrimidine (C or T) residues. Major products are 5′-phosphorylated di-, tri- and
tetranucleotides.
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Ribonuclease A (RNase) is an enzyme catalysing the hydrolytic cleavage of phos-
phodiester linkage in the RNA backbone. Cleavage preferentially occurs at the 3′ end
of pyrimidine residues and degrades the RNA into 3′-phosphorylated mononucleotides
and oligonucleotides.
Lysozyme is an enzyme catalysing the hydrolysis of linkages present in the bacteria
cell wall.
The bacterial suspension was then subjected to three freeze-thaw cycles to perform
lysis of the cell walls and centrifuged to remove the cellular debris. The supernatant
was then purified by column chromatography.
Fast protein liquid chromatography. Fast Column Liquid Chromatography is an
ion exchange column chromatography used to separate and/or purify proteins from
mixtures (Figure 6.4). Analytes are retained on the stationery phase, which displays
opposite ionic functional groups, by coulombic interactions.
Cation exchange chromatography retains positively charged molecules on a negatively
charged stationery phase. Anion exchange chromatography retains negatively charged
molecules on a positively charged stationery phase.
Figure 6.4: Fast column liquid chromatography apparatus. A sample is introduced into a
sample loop of 2 mL volume. A buffered aqueous solution known as the mobile phase carries
the sample from the loop onto a column (stationary phase). The analytes are then detected by
conductivity and UV/visible absorbance.
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Proteins have a wide number of both negatively and positively charged functional
groups. Ion exchange chromatography separates proteins according to their net charge
which is dependent on the mobile phase whose pH can be varied owing to the separation
needed.
H human apoferritin was purified using an anion exchange chromatography and the
different fractions were then analysed by SDS-PAGE (Figure 6.5).
Figure 6.5: SDS-PAGE of the FPLC fractions of H human apoferritin.
On the electrophoresis gel, the characteristic band of the H subunit at 21 kDa was
observed in different fractions (surrounded by the purple rectangle in Figure 6.5). Al-
though, H human apoferritin has been synthesized successfully, it is clear that the
purification of the protein needs to be further developed. After SDS-PAGE, Grace et
al. purified the synthesized heteropolymer of apoferritins with a second size exclusion
chromatography.
6.3.2 Incorporation of methionine analogues
Organic synthesis of the methionine analogues. Alkyne and azide methionine
analogues were prepared by members of Prof. Neil Thomas and Dr. Chen Wang groups
(Figure 6.6).
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Figure 6.6: Methionine analogues.
Aminohexynoic acid was prepared in two steps consisting of Swern and Strecker
reactions (Figure 6.7).[411, 412] Swern reaction led to the oxidation of 3-butyn-1-ol (1)
into aldehyde (2). Compound (2) was found to be very unstable and thus was used
as crude during the Strecker reaction. Amino acid (3) was obtained after hydrolysis of
the aminonitrile intermediate.
Figure 6.7: Synthesis of aminohexynoic acid.
Azidohomoalanine was prepared from the protected aspartic acid (Asp) N -tert-
butoxycarbonyl-L-Asp-4-benzyl ester (4) (Figure 6.8). Acid group of (4) was protected
using isobutylchloroformate and N -methylmaleimide (NMM) followed by reduction
with sodium borohydride led to the formation of the alcohol (5). Compound (5) was
then mesylated into (6). Sodium azide was used to exchange the -OMs group of (6) with
an azide function giving compound (7). Finally, deprotection of the t-butyloxycarbonyl
(Boc) and benzyl (Bn) groups gave the desired amino acid (8).[412]
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Figure 6.8: Synthesis of azidohomoalanine.
Azidonorleucine was prepared from N -α-Boc-lysine (Figure 6.9).[413] Sodium azide
was added to triflic anhydride (Tf2O, 9) leading to TfN3 (10). The addition of the
azido group from (10) to the Boc-protected lysine (11) was catalysed by copper(II)
forming the Boc-protected azidonorleucine which underwent deprotection of the Boc
group with concentrated hydrochloric acid giving azidonorleucine (13).
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Figure 6.9: Synthesis of azidonorleucine.
H and L human apoferritins expressions with methionine analogues. The
incorporation of the different methionine analogues was studied following the protein
expression reported by van Hest et al..[401]
First H and L apoferritins were grown in M9 medium containing all amino acids
including methionine. After a few hours of growth (OD600 = 0.4), a medium shift
was performed: the cells were sedimented and washed several times with M9 medium
containing no amino acids. These washing steps led to depletion of natural methionine
substrate in the medium. The cells were resuspended in M9 and divided into 10 aliquots
of M9 medium containing the methionine analogue (Table 6.1). All cultures were tested
by analysis by Western blotting.
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Protein Incubation
IPTG (mM)
Incubation
H or L apoferritin temperature ( ◦C) time (h)
1 positive control 37 0.75 2
2 negative control 37 0.75 2
3 aminohexynoic acid 37 0.75 2
4 azidohomoalanine 37 0.75 2
5 azidonorleucine 37 0.375 2
6 azidonorleucine 37 1.5 2
7 azidonorleucine 37 0.75 2
8 azidonorleucine 37 0.75 4
9 azidonorleucine 20 0.75 o/n
Table 6.1: Expression conditions of H and L human apoferritins containing natural methionine
(positive control), no methionine (negative control) and methionine analogues (aminohexynoic
acid, azidohomoalanine, azidonorleucine).
Western blotting. Immunoblotting or Western blotting is a technique used to detect
a specific protein by an antigen/antibody recognition. Usually, samples are solubilized
and denatured with SDS. The different antigens are then separated by SDS-PAGE and
electrophoretically transfered on a nitrocellulose membrane where they are immunode-
tected with a primary antibody (Figure 6.10). The antigen/antibody complexes are
finally identified with horseraddish peroxidase (HRPO).[414]
HRPO is an enzyme catalyzing the oxidation of a substrate, the luminol (Fig-
ure 6.10).
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Figure 6.10: Detection of protein target using HRPO/luminol chemiluminescent system.
When luminol reacts with the hydroxide salt, a dianion is formed. The oxygen produced
from the hydrogen peroxide then reacts with the luminol dianion. The product of this
reaction, an organic peroxide, is very unstable and immediately decomposes with the
loss of nitrogen to produce 3-aminophthalic acid with electrons in an excited state. As
the excited state relaxes to the ground state, the excess energy is liberated as a photon,
visible as blue light (λmax = 425 nm).
Figure 6.11 shows the Western blotting performed for L human apoferritin contain-
ing the three different methionine analogues aminohexynoic acid, azidohomoalanine
and azidonorleucine.
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Figure 6.11: Western blot results.
From the images with no source of light (chemiluminescence from the luminol) and
the gel under white light, a band around 19 kDa can be seen which is the molecular
weight of L apoferritin subunit. Nevertheless, this band is observed in all samples,
even the negative sample which does not contain methionine. This implies that protein
expression starts before adding IPTG to the medium. To clearly see the formation of
L apoferritin with the methionine analogues, specific reagents should be used to label
azido and alkyne molecules. These hypothetic experiments are described in the chap-
ter 7.
Other techniques of observing the incorporation of analogues into proteins have
been reported. Coumarin was used to successfully label methionine analogues incorpo-
rated into mammalian[416] and bacterial[415] cells. Tirrell et al. reported the labelling
of the azido-modified surface of E. coli with a biotinylated alkyne reagent.[417] Also,
azido methionine analogues can be labelled through the Staudinger ligation where azido
groups react with a phosphine reagent.[418] Bertozzi et al. have reported the use of
these two techniques to label azides incorporated into proteins.[419–421]
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6.4 Conclusion
The introduction of specific and highly functional groups into human apoferritin protein
has been studied. Un-natural methionine amino acids with azido and alkyne groups
were synthesised and used for the generation of apoferritin. These analogues were in-
corporated as substitutes for natural methionine residues using methionine auxotroph.
Western blot analysis showed characteristic bands proving the synthesis of human apo-
ferritin with natural methionine as well as with methionine analogues which led to the
conclusion that the incorporation of new functional groups into apoferritin is possible
and could be further developed for the binding of apoferritin to biomolecules.
Chapter 7
Conclusions and future work
To summarize, we have synthesised thiol-capped PbS quantum dots of different sizes in
aqueous solution and reported their fluorescence properties. We observed a thermally
activated increase of the emission linewidth and have rationalised this behaviour in
terms of dephasing of the electronic states by interaction with longitudinal optical
phonons.
PbS QDS have been incorporated in the cavity of the protein cage apoferritin by
both reassembly and the ‘nanoreactor’ routes in aqueous solution. The AFt-PbS com-
posites have a photoluminescence emission at ∼ 1 µm, which is in the wavelength
window of low absorbance of biological media. The apoferritin cages provide an exte-
rior coat to the quantum dot that is amenable to the attachment of further proteins,
saccharides or other biomolecules using standard conjugation chemistry.
AFt-PbS composites have been characterised by atomic force microscopy, transmis-
sion electron microscopy, energy dispersive X-ray, high angular dark field and electron
energy loss techniques, selected area diffraction pattern, photoluminescence and poly-
acrylamide gel electrophoresis.
Further work will involve the purification of PbS quantum dots and PbS-encapsulated
apoferritin composites by ultracentrifugation using speeds of 20,000/150,000 g for PbS/-
AFt-PbS composites respectively.[198] The different density levels could be separated
using a fractionator and further analysed using UV-near IR spectrophotometer. This
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technique would allow the separation of empty AFt, non-encapsulated PbS dots and
AFt-PbS composites.
PbS QDs could be used as energy acceptors in a bioluminescence resonance energy
transfer where luciferin acts as the energy donor. BRET allows the emission of PbS
QDs whilst negating the use of laser excitation, which could be harmful to the human
body. Such a system could be further developed to produce photoluminescence emission
for our AFt-PbS composites.
By using human apoferritin rather than horse spleen apoferritin, the immunogenic-
ity of the systems could also be reduced for in vivo use once the toxicity of the composite
has been determined. The Western blot technique indicated the possibility of the in-
corporation of methionine analogues into human apoferritin. To improve this result, we
can perform other detection methods such as fluorescence using coumarin or a FLAG
peptide.
In order to simplify the purification of H and L human homopolymer apoferritins
and thus the purification of modified apoferritins with methionine analogues, the coding
regions of H and L could be inserted into a vector bearing a polyhistidine-tag such as
vector pET-30 (Figure 7.1). An His (histidine) tag is an amino acid motif in proteins
that consists of at least six histidine residues, often at the N - or C -terminus of the
protein.
Figure 7.1: Simplified structure of plasmid pET-30a.
This His tag would make the purification steps easier, but may prevent the assembly
process or inclusion of the QDs in the apoferritin cavity. Indeed, proteins synthesised
with the His tag can be purified using affinity column chromatography as histidine binds
to Ni2+ with strong selectivity. The tag can then be easily removed from the protein
by the enzymes exopeptidase/endopeptidase which act to break peptide bonds. This
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project would involve several steps: 1) polymerase chain reaction (PCR) (duplication
of H/L inserts), 2) ligation of H/L inserts into pET-30a, 3) transformation into cells
followed by expression and purification of the proteins and finally 5) removal of the His
tag.
Primers to replicate the coding regions of H and L apoferritins were designed at the
Molecular Foundry with the restriction enzymes EcoRI and XhoI:
Light chain apoferritin:
Sense primer:
CCTAGAATTCAGCTCCCAGATTCGTCAGAATTATTC, ’LCHFS1’
Antisense primer:
AATTCTCGAGTTAGTCGTGCTTGAGAGTGAGCCTTT, ’LCHFA1’
Heavy chain apoferritin:
Sense primer:
ACTGGAATTCATGACGACCGCGTCCACCTCGCAGGT, ’HCHFS1’
Antisense primer:
CCGGCTCGAGTTAGCTTTCATTATCACTGTCTCCCAGG, ’HCHFA1’
ACGGCTCGAGTTAGCTTTCATTATCACTGTCTCCCAGG, ’HCHFA2’
Chapter 8
Experimental techniques
8.1 Sample preparation
8.1.1 Preparation of apoferritin from ferritin
UV-visible spectra were performed on Varian Cary 100 Bio spectrophometer ther-
mostatted at 22 ◦C.
Dialyses bags were purchased from Medicell International Ltd (Visking type, MWCO
12-14,000 Da, size 11, 1.5 inches (38.1 mm) diameter, 56-59 mm width, 11.4 cm length).
The pH used during the apoferritin synthesis was adjusted using the pH meter PIC-
COLO HI 1290 with an amplified electrode from HANNA.
Horse spleen ferritin (85 mg mL−1 and 111 mg mL−1, sterile filtered solution of ferritin
in 0.15 M NaCl) and sodium acetate were purchased from Sigma-Aldrich. The reducing
agent mercaptoacetic acid (98%) was purchased from Lancaster.
Before use, dialysis bags were washed first with hot water and then with deionized
water.
Apoferritin was prepared by using the procedure described in references [334, 335]. The
native horse spleen ferritin protein (255 mg, 0.34 mmol) was diluted in 27 mL 0.1 M
NaOAc buffer (2.7 mmol, pH 5.5) and placed into a dialysis bag. The protein was first
dialysed against 0.1 M NaOAc buffer (820 mL, 0.082 mol) at pH 5.5 for 20 min under
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N2. Mercaptoacetic acid (0.03 M, 2 mL, 60 µmol) was then added to the buffer and
dialysis was continued for 2 hours against 0.1 M NaOAc pH 5.5 (820 mL, 0.082 mol);
further mercaptoacetic acid (0.03 M, 1 mL, 30 µmol) was added and dialysis continued
for an additional hour against 0.1 M NaOAc pH 5.5 (820 mL, 0.082 mol); finally, the
protein was dialysed against fresh 0.1 M NaOAc buffer (820 mL, 0.082 mol) at pH
5.5 for 20 minutes and purged with N2. This process was repeated as necessary until
reaching a complete decolouration of the ferritin solution.
Apoferritin was then stored under N2 at room temperature with 0.1 M NaOAc buffer
(pH 5.5) refreshed every day.
8.1.2 Size exclusion chromatography
The purification by size exclusion chromatography was run on a Pharmacia Biotech
A¨KTA explorer and FRAC-900 with a Superdex 75 column (< 100 kDa) of 30 cm
height, 10 mm diameter and 24 mL bed volume.
First, the Superdex column was rinsed with the eluent consisting of a mixture of 0.1 M
NaOAc pH 5.5 and 0.15 M NaCl.
Ferritin (8.5 mg mL−1) and apoferritin (8.5 mg mL−1) samples were filtered on a filter
unit (Sartorius Minisart 0.20 µm) removing aggregates larger than 0.20 µm. This fil-
tration clarified the sample, which was a milky suspension before filtration and became
a pale-yellow clear solution after elimination of the aggregates. Then, 0.25 mL of the
protein samples (8.5 mg mL−1) were injected into the column, and the conditions set
at a pressure of 0.74 MPa, a flow rate of 0.5 mL min−1, an absorption at 280 nm to
detect the presence of protein units and the fractions collected had a volume of 0.5 mL.
8.1.3 SDS-PAGE of apoferritin
Gel electrophoresis were run in a tank from ATTO Corporation (AE-6450) and a Pow-
erPac Basic 300 V/400 mA/75 W from BioRad.
The staining solution was prepared as a solution of Coomassie Blue R250/Brilliant Blue
(0.625 g) in 250 mL of methanol, 50 mL of acetic acid and 20 mL of water. Fast destain
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solution and low destain solution were prepared as 40% methanol + 10% acetic acid
and 10% methanol + 7.5-10% acetic acid respectively. Staining and destaining were
performed by shaking on an orbital shaker KS250 (IKA Labortechnik, Germany).
TEMED (99%) was purchased from Sigma-Aldrich. Acrylamide-bisacrylamide (w/v
37.5:1) and the prestained protein marker used as the ladder during SDS-PAGE gel
electrophoresis, broad range 6-175 kDa (aprotinin 7 kDa, lysozyme 17 kDa, CBD-
BmFKBP13 25 kDa, triosephosphate isomerase 30 kDa, aldolase 46 kDa, MBP-CBD
58 kDa, MBP-paramyosin 80 kDa, MBP-β-galactosidase 175 kDa) were purchased from
Severn Biotech Ltd and New England Biolabs respectively.
The SDS-PAGE gel was prepared by adding components in the following order:
1. Preparation of the 16% resolving gel (positively charged): to 3.64 mL of water
were added successively 4 mL of Tris 1 M at pH 8.8, 160 µL of SDS 10%, 8.2 mL
of acrylamide 30%, 200 µL of APS 10% and 20 µL of TEMED. The ingredients were
mixed gently and poured into the glass plate assembly. The gel was left to polymerise
for 30 min and then some isopropanol was added to ensure a flat surface and exclude
the air. After 15 min, the isopropanol was washed off with plenty of water.
2. Preparation of the 6% stacking gel: to 2.7 mL of water were added successively
1.25 mL of Tris 1 M at pH 6.8, 50 µL of SDS 10%, 1 mL of acrylamide 30%, 80 µL of
APS 10% and 8 µL of TEMED. The ingredients were mixed gently and poured onto
the top of the resolving gel and insert the comb. The gel was left to polymerise for 30
min and then the comb was removed.
While preparing the gel, 4 samples of protein were prepared as following: 20 µL of
each solution (ferritin (8.5 mg mL−1 and 4.25 mg mL−1) and apoferritin (8.5 mg mL−1
and 4.25 mg mL−1)) were mixed with 20 µL of the loading buffer (100 mM Tris-HCl
pH 6.8, 4% SDS, 0.2% bromophenol blue, 20% glycerol, 4% 2-mercaptoethanol). The
control sample was the prestained protein marker of broad range (6-175 kDa) which is
a mixture of purified proteins covalently coupled to a blue dye that resolves to 8 bands
of even intensity when electrophoresed. All samples were heated 1 min at 99 ◦C. The
gel was installed in the tank and filled with electrophoresis buffer (28.8 g of glycine, 6
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g of Tris, 20 mL of 10% SDS, pH 8.8). Each solution (20 µL) were deposited on the
gel, the top tank was installed and the voltage was set on 130 V (current 28 A) for 15
min and then set on the maximum voltage (300 V).
After the migration was completed (1 h 15), the gel was removed and stained with
Coomassie Blue R250/Brilliant Blue (0.625 g in 250 mL of methanol, 50 mL of acetic
acid and 20 mL of water) for 20 min. The gel was then destained 10 min in a fast
destain and 48 h in a low destain.
8.1.4 BCA assay on ferritin and cationized ferritin
UV-Visible spectra were performed on an Agilent 845 spectrophotometer.
BCA assays were performed on a Tecan Sunrise instrument after incubation of the
samples in a water bath Grant LTD 6G.
Bicinchoninic acid and copper(II) sulphate (4% (w/v) CuSO4
.5H2O in water, pH ∼4)
were purchased from Sigma-Aldrich.
The protein cationized ferritin and TEMED (99%) were purchased from Sigma-Aldrich.
The bicinchoninic assay is an assay employed in biochemistry to determine the level of
protein in a given sample. The protein concentration is defined by a colour variation
from green to purple depending on the amount of protein present which can then be
measured by colorimetric techniques.[422]
Different conditions were tested:
1) Solutions of 0.5 mg mL−1 and 0.25 mg mL−1 of ferritin and cationized ferritin
respectively were prepared in deionized water.
2) Solutions of ferritin (0.11, 0.21, 0.43, 0.64 and 0.85 mg mL−1) and cationized
ferritin (0.07, 0.14, 0.28 and 0.55 mg mL−1) were prepared in 0.15 M NaCl solutions.
In both cases, the following solutions were prepared: a solution of 10 mL of bicinchoninic
acid and 200 µL of copper(II) sulphate.
Standards were composed of buffer NaOAc (0.1 M, pH 5.0) and BSA (1 mg mL−1 in
0.15 NaCl, 1.5 10−5 mol) as described in the following table:
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Standard buffer (µL) BSA (µL) BSA final concentration (mg mL−1)
1 200 0 0
2 180 20 0.1
3 160 40 0.2
4 140 60 0.3
5 120 80 0.4
6 100 100 0.5
Then 800 µL of BCA-CuII solution was added to each standard (200 µL) and to ferritin
and cationized ferritin solutions (200 µL) as well. Incubation was followed for 30 min
at 40 ◦C.
The protein concentrations of the different samples of ferritin and cationized ferritin
were determined by measuring their absorbance at 562 nm and comparing the results
with the absorbance of BSA protein standards.
8.1.5 ICP-MS analysis
Samples for ICP-MS analysis were diluted using a Microlab 500 series Hamilton and
analysed under an ICP mass spectrometer X series II from Thermo electrocorporation.
ICP-MS allows the determination of elements with mass ranges from 7 to 250. The
apparatus consists of a plasma producing ions (ionization via helium plasma) and a
mass spectrometer that separates and detects the ions. Commonly, the sample is
introduced as a liquid solution and submitted to a nebulizer which converts the solution
into an aerosol. The helium carrier gas is exposed to radio frequency inducing the
following reaction He −−→ He++e – thus converting the gas into a plasma. The sample
is then exposed to this plasma whose temperature is high enough to generate the
formation of ions which are finally detected by the mass spectrometer.
Ferritin (85 mg mL−1) and apoferritin (8.5 mg mL−1) samples were prepared as
solutions in the diluent for blood analysis (0.1% Triton, antifoam-B, 1% nitric acid) to
avoid deposition of protein on any of the tubing as follows:
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1. Control × 20,000 : 0.5 mL of × 1,000 dilution of the control sample and addition
of 9.5 mL of diluent to give overall × 20,000 dilution i.e. expect 0.11 ppm = 110 ppb,
2. Test × 20,000 : 0.5 mL of × 1,000 dilution of the test sample and addition of
9.5 mL of diluent to give overall × 20,000 dilution,
3. Test × 5,000 : 2 mL of × 1,000 dilution of the test sample and addition of 8 mL
of diluent to give overall × 5,000 dilution,
4. 2nd Test × 5,000 : repeat of above,
All samples were then analysed by the ICP mass spectrometer.
8.1.6 Solubility of ferritin and cationized ferritin in organic media
Centrifugations were performed using a C9405-VWR Galaxy 5D microcentrifuge.
In order to render water-soluble molecules dispersible into organic solvents, surfac-
tants are commonly used to form micelles around the desired molecules. Transfer into
dichloromethane, hexane and toluene were achieved using the widespread surfactant
aerosol OT.
Solutions of protein-AOT were prepared with different molar ratios (moles of basic
amino acids1:moles of surfactant). For examples:
• A 1:1 molar ratio ferritin/AOT solution was prepared by mixing a solution of
ferritin (commercially available, 85 mg mL−1) and a solution of AOT (5 mg mL−1,
1.12 10−5 mol) as following: a solution of AOT (4.3 10−4 mmol, 0.19 mg, 380 µL)
in the organic solvent (620 µL of dichloromethane, hexane or toluene) was added to
a solution of ferritin (4.3 10−4 mmol, 10 mg, 118 µL) in buffer NaOAc (10 mM, 882
µL, pH 3.8) and stirred at room temperature for 10 min, then centrifuged for 2 min at
4,611 g (8,000 rpm).
• A 1:1 ratio cationized ferritin/AOT solution was prepared using a solution of
cationized ferritin (commercially available, 11 mg mL−1) and the solution of AOT (5
mg mL−1, 1.12 10−5 mol) as follow: a solution of AOT (8.35 10−4 mmol, 0.37 mg, 740
µL) in the organic solvent (260 µL of dichloromethane, hexane or toluene) was added
1lysine, arginine + glutamic and aspartic acid residues assuming that they are all cationized.
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to a solution of cationized ferritin (9.38 10−4 mmol, 10 mg, 909 µL) in phosphate buffer
(0.02 M, 91 µL, pH 7.0) and stirred at room temperature for 10 min, then centrifuged
for 2 min at 4,611 g (8,000 rpm).
The effective transfer of the cationized ferritin into the organic phase was observed
by the significant orange colouration of the phase due to the presence of the protein.
The aqueous and organic phases were analysed by measuring their absorbance over the
range 190-900 nm.
8.1.7 Preparation of the cationized ferritin
Hexamethylenediamine (98%) and N,N -dimethyl-1,3-propanediamine, hexamethylene-
diamine (97%) were purchased from Sigma-Aldrich.
The modification of carboxyl groups of ferritin into amino groups was carried out fol-
lowing the conditions reported previously by Danon et al.[343]
• Formation of tertiary amines using N,N -dimethyl-1,3-propanediamine:
In a 50 mL beaker placed on a magnetic stirrer, 4 mL of a 2 M aqueous solution of
DMPA (817.4 mg, 8 mmol) were placed. The pH was adjusted to pH 6.5 with 0.2 M
HCl followed by the addition of 1 mL of a 10% ferritin solution (85 mg mL−1, 0.1 mL
in 0.9 mL 0.15 NaCl) was added to the previous DMPA solution.
To the orange solution obtained, the coupling agent EDC (400 mg, 2.08 mmol) was
added and the pH maintained at 6.5 by addition of 0.2 M HCl with continuous stirring
until no measurable changes in pH were recorded (∼ 2 h). Finally, the reaction mixture
was transferred to a stoppered vial and observed to be stable at RT for several months.
• Formation of primary amines using hexamethylenediamine:
In a 250 mL beaker placed on a magnetic stirrer, 4 mL of a 2 M aqueous solution of
HMD (930 mg, 8 mmol) were placed. The pH was adjusted to 6.5 with 0.2 M HCl
followed by the addition of 1 mL of a 10% ferritin solution (85 mg mL−1, 0.1 mL in 0.9
mL 0.15 NaCl) was added to the previous HMD solution.
To the pale orange solution obtained, EDC (400 mg, 2.08 mmol) was added and the pH
maintained at 6.5 by addition of 0.2 M HCl with continuous stirring until no measurable
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changes in pH were recorded (∼ 2 h). Then the reaction mixture was stored in a
stoppered vial and found to be stable at RT for several months.
8.1.8 Determination of amine groups in the cationized ferritin
Incubations were performed in a WTB Binder incubator.
L-alanine (99%) was purchased from Sigma-Aldrich.
The level of cationization of ferritin was determined through a coupling reaction of
the primary amine groups of the HMD-cationized ferritin with trinitrobenzene sulfonic
acid.
First, a bicarbonate buffer NaHCO3 (0.1 M, 11.76 g, 1,600 mL, pH 8.2) was prepared
as a stock solution.
Alanine (4 mg, 4.5 10−5 mol) standard was also made as stock solutions of 20 µg mL−1.
Aliquots of this standard was dissolved in 0.1 M NaHCO3 pH 8.2 to a concentration of
15.4, 10 and 5 µg mL−1.
The aqueous solution of cationized ferritin synthesized using hexamethyldiamine (5
mL) was dissolved into 0.1 M sodium bicarbonate pH 8.2 (5 mL) at a concentration of
50 µg mL−1.
TNBS (1 mL, 3.47 10−3 mol, 5%) was dissolved in 0.1 M NaHCO3 pH 8.2 (499 mL) at
a concentration of 0.01% (w/v).
The blocking of the amino groups was carried out by adding 0.5 mL of TNBS solution
to 1 mL of each sample (alanine, cationized ferritin). After mixture, all samples were
incubated at 37 ◦C for 2 h. Then 0.5 mL of 10% SDS and 0.25 mL of 1 N HCl were
added to the samples.
The degree of cationization was determined at 335 nm by comparison between the
cationized ferritin and alanine.
8.1.9 Synthesis of PbS quantum dots
For the preparation of PbS dots, lead(II) acetate trihydrate (99.99%), 2,3-dimerca-
ptopropanol, monothioglycerol (98%), triethylamine (minimum 99%) and sodium sul-
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phide were purchased from Sigma-Aldrich.
PbS nanocrystals were prepared following the procedure reported by Bakueva et al..[301]
A 60 mL solution containing lead acetate trihydrate (Pb(CH3COO)2
.3H2O) (0.364 g,
0.96 mmol) and a mixture of thiols, i.e. thioglycerol (0.52 mL, 0.006 mol) and dithio-
glycerol (0.20 mL, 0.002 mol), which act as capping agents yielding a yellow solution of
Pb:TGL:DTG 1:6:2 was prepared. The pH of the Pb2+ precursor solution was adjusted
to 11.0 by adding dropwise triethylamine (∼ 4 mL) until complete decolouration of the
solution (pH ∼ 11.0).
The synthesis of the dots was completed by adding a 0.1 M colourless solution of sodium
sulphide Na2S under vigorous stirring in deionized water in different molar ratios:
Molar ratio Pb2+ precursor solution Na2S solution Colour
1:0.1 15 mL 0.25 mL pale brown
1:0.2 15 mL 0.5 mL pale brown
1:0.3 15 mL 0.75 mL pale brown
1:0.5 15 mL 1.25 mL dark brown
1:0.6 15 mL 1.50 mL dark brown
1:0.7 15 mL 1.75 mL black
Samples 1:0.1 and 1:0.2 have been prepared as well with double the concentration of
thiols. To 30 mL of Pb2+ solution, 0.26 mL of TGL and 0.10 mL of DTG were added
followed by the addition of Et3N to adjust the pH to 11.0. The synthesis of PbS
quantum dots was completed by adding a solution of 0.1 Na2S in deionized water as
given above.
8.1.10 Synthesis of PbS-apoferritin composites
As described in the discussion part, AFt-PbS composites were synthesized using two
routes of encapsulation.
For the nanoreactor route, we injected Pb2+ precursor solution (5 mL, 0.08 mol)
and 0.1 M Na2S (0.25 mL to 0.58 mL for Pb/S molar ratio (MR) varying from 1:0.3
to 1:0.7) to a solution of apoferritin in deionized water (5 mL, 0.09 mmol) at pH = 5.5
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under vigorous stirring. The resulting solution was mixed for 15 minutes after the
injection.
For the reassembly route, the pH of a 5 mL solution of preformed PbS QDs was
adjusted to 9.5 by adding 0.1 M HCl. Apoferritin (5 mL, 0.09 mmol) was adjusted to
pH = 2.0 by dialysis against a 0.1 M NaCl solution (150 mL), whose pH was controlled
by 2 M HCl. Then disassembled apoferritin was added slowly to the preformed quantum
dots.
Both syntheses were carried out under a N2 atmosphere. The solutions were stored in
a fridge at a temperature of 278 K under a N2 atmosphere.
For the centrifugation experiment, the AFt-PbS solutions were centrifuged at 402 g for
5 min at 16 ◦C using a Rotor S4180 in a Beckman GS-15R centrifuge.
8.1.11 Synthesis of dihydrolipoic acid-capped PbS QDs
Reduced lipoic acid (98%) used for the surface modification of thiol-capped PbS was
purchased from Sigma-Aldrich.
The preparation of DHLA-capped PbS nanocrystals was derived from the synthesis of
PbS quantum dots reported in the previous paragraph by simply exchanging the DTG
ligands by lipoic acid in order to obtain a molar ratio Pb:TGL:DHLA of 1:6:2.
The capping agent thioglycerol (0.52 mL, 1.5 10−3 mol) was added to a Pb2+ precursor
solution of lead(II) acetate trihydrate (0.379 g, 2.5 10−4 mol) suspended in deionized
water (60 mL) under N2 yielding a yellow solution with a Pb:TGL MR of 1:6.
To 15 mL of the Pb:TGL solution, 100 mg of dihydrolipoic acid was added (4.8 10−4
mol, 1.134 g cm−3) and the pH adjusted to 11.0 with ∼ 0.9 mL of triethylamine giving
a colourless solution.
PbS synthesis was achieved by the addition of 0.1 M Na2S solution in deionized water
to the Pb precursor solution.
Pb/S molar ratios 1:0.3, 1:0.5 and 1:0.7 were synthesized:
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Molar ratio Pb2+ precursor solution Na2S solution Colour
1:0.3 5.3 mL 0.25 mL dark brown
1:0.5 5.3 mL 0.41 mL dark brown
1:0.7 5.3 mL 0.58 mL dark brown
Dihydrolipoic acid-capped PbS quantum dots were observed to be stable for months
when kept in the dark under N2 at 4
◦C.
8.1.12 Bioluminescence of firefly luciferase from L. mingrelica
BRET experiments were performed using the recombinant firefly luciferase from Lu-
ciola mingrelica (minimum 95%), synthetic D-luciferin and adenosine 5′-triphosphate
(99%) from Sigma-Aldrich.
The reaction of luciferase, luciferin, ATP and O2 results in the emission of light.
In our system, the luciferase (5 mg, 2 106 light units per mg of protein) was used as
supplied: a colourless solution of approximately 10 mg of protein per mL of 23 mM
Tris acetate, 5 mM MgSO4, 1 mM EDTA, and 50% (v/v) glycerol.
D-luciferin (5 mg, 1.65 10−5 mol) was diluted in Tris acetate buffer pH 6.5 to a con-
centration of 0.5 mg mL−1 (faint yellow solution).
ATP (150 mg, 2.72 10−4 mol) was prepared as a 50 mg mL−1 colourless solution in
deionized water.
Luciferase was kept hermetically closed at −20 ◦C whilst D-luciferin and ATP were
stored at 4 ◦C. During experiments, all solutions were kept on ice and D-luciferin was
protected from light.
An ATP solution (0.25 mL) was added to 2.4 mL of D-luciferin solution in a plastic
cuvette followed by the introduction of 1.3 µL of luciferase.
Bioluminescence measurements were carried out using a Perkin Elmer LS55B lumines-
cence spectrometer thermostatted at 4 ◦C. Readings were taken over the range 250-800
nm at a speed of 500 nm min−1 and slit width 5.0 nm in the absence of excitation.
Luminescence measurements were carried out over 1 h without any noticeable change
in the luminescence emission/intensity.
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8.1.13 BRET experiments using firefly luciferase as the energy donor
and PbS dots as energy acceptors
In order to create an efficient BRET, the donor and acceptor molecules have to be
in close proximity. Thus, EDC was used as a coupling agent between luciferase and
dihydrolipoic acid-capped PbS dots.
EDC (30 mg) was dissolved in deionized water (30 mg mL−1).
For optimization of the coupling, EDC was introduced in a 1:1 molar ratio to DHLA.
Thus to 0.5 mL of DHLA-capped PbS QDs (1.6 10−5 mol of DHLA), 0.1 mL of EDC
solution and 1.3 µL of luciferase solution (10 mg mL−1) were introduced in the glass vial
used for PL measurement and allowed to mix at room temperature for 2 min. Then,
0.25 mL of ATP solution (50 mg mL−1) was added followed by the rapid addition of
2.4 mL of D-luciferin.
Photoluminescence measurement of the DHLA-capped was carried out in a fully dark
room to avoid any excitation of the self-illuminating system luciferin-luciferase and
run over the range 900-1,400 nm, integration time 60 s, increment 3 nm, slits 2.0.
Bioluminescence measurements were carried out as described in section 8.1.12.
8.2 Measurements techniques
8.2.1 Luminescence spectroscopy
For PL experiments, the PbS quantum dots and AFt-PbS composites were studied as
liquid solutions in a glass vial and deposited on a glass substrate. The optical excitation
was provided by the 514.5 nm line of an Ar+ laser. The luminescence was dispersed by
a 1/2 m monochromator and detected by a cooled (InGa)As photodiode.
Photoluminescence is a process in which a substance submitted to an excitation source
(here Ar+ laser) will absorb photons. Electrons are delocalised to an higher energy
level whose returns to the ground state are accompanied by the emission of photons.
PL detects an optical transition from an excited electronic state to a lower electronic
state, the time period between absorption and emission of photons is extremely short
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(∼ 10 ns).[423]
Figure 8.1: PL principle.
8.2.2 Atomic force microscopy
For Atomic Force Microscopy (AFM) measurements, the PbS QDs and AFt-PbS com-
posites were dispersed onto a polished (100)-oriented p-type Si-substrate. Following
the dilution of the solution with deionised water to 1 part in 100, a small drop was
then deposited on the substrate and spin-coated for 30 seconds at a speed of 250 rph
(revolutions per hour).
The atomic force microscope was invented in 1986 by Binnig, Quate and Gerber and
is one of the foremost tools for imaging, measuring and manipulating matter at the
nanoscale.[424]
Like all other scanning probe microscopes, the AFM utilises a sharp probe moving over
the surface of a sample in a raster scan. In the case of the AFM, the probe is a tip on
the end of a cantilever, which bends in response to the force between the tip and the
sample.
The diagram illustrates how this works: as the cantilever flexes, the light from the laser
is reflected onto the split photo-diode. By measuring the difference signal, changes in
the bending of the cantilever can be measured. When the tip is brought into proximity
of a sample surface, forces between the tip and the sample lead to a deflection of the
cantilever according to Hooke’s law.
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Figure 8.2: AFM principle.
8.2.3 Transmission electron microscopy
Transmission electron microscopy is an imaging technique based on the principle of
diffraction of electrons and can reach an enlargement of 1,000,000. The TEM principle
was developed by Max Knoll and Ernst Ruska in 1931.
The electron beam passes through the sample. Depending on the thickness, the density
or the chemical composition of the sample, the electrons are more or less absorbed.
The enlarged picture appears on a fluorescent screen or layer of photographic film or
is detected by a CCD camera. This method is used in biology to observe cells or thin
sections of organs.
8.2.4 High resolution transmission electron microscopy
High Resolution Transmission Electron Microscopy (HRTEM) images were recorded on
a JEOL2011EX microscope operating at 200 kV.
High resolution transmission electron microscopy is an imaging mode of the TEM al-
lowing the determination of the crystallographic structure of a given substance.
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8.2.5 High angle annular dark field scanning transmission electron
microscopy
High Angle Annular Dark Field Scanning Transmission Electron Microscopy (HAADF-
STEM) was performed with a JEOL 2010F microscope operating at 200 keV and
equipped with a GIF camera providing an energy resolution of about 1.6 eV.
High angle annular dark field scanning transmission electron microscopy is an imaging
technique highly sensitive to the atomic number where scattered electrons are collected
with an annular dark-field detector.
8.2.6 Electron energy loss spectroscopy
Electron Energy Loss Spectroscopy (EELS) was performed with a JEOL 2010F mi-
croscope operating at 200 keV and equipped with a GIF camera providing an energy
resolution of about 1.6 eV.
Electron energy loss spectroscopy was developed by J. Hillier and R. F. Baker in
1944.[425] When a substance is exposed to an electron beam, a part of the electrons
is inelastically scattered and which means these electrons lose their energy and have
deflected paths. Elemental composition and atomic bonding state can be determined
by measuring the amount of energy loss using an electron spectrometer.
8.2.7 Energy dispersive X-ray spectroscopy
Energy Dispersive X-Ray (EDX) spectra were recorded with an Oxford Instruments
ultrathin-window EDX detector. The principle of EDX is based on the fact that each
element of the periodic table have a unique response (unique electronic structure) to
electromagnetic waves. The electrons of a substance exposed to a photon beam are
excited which results in the formation of electron-hole. An electron of higher energy
fills the hole and the excess of energy of that electron is released as an X-ray which
creates a spectral line specific to the element.
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8.3 Expression of H and L human apoferritins
The plasmids pET-11a (rHuHFt) and pET-26b(+) (rHuLFt) were kindly provided by
Dr. Steven Aust from Utah State University. B834(DE3)pLysS competent cells were
supplied by Novagen. LB broth and agarose were purchased from Sigma-Aldrich, Agar
from Becton-Dickinson. Antibiotics were used from stocks: ampicillin (Amp) 100 mg
mL−1, chloramphenicol (Chl) 30 mg mL−1, kanamycin (Kan) 50 mg mL−1. IPTG
(isopropyl β-D-1-thiogalactopyranoside) was used from a stock sample of 0.1 M. DNase
I, RNase (31 kDa) I and lysozyme were used from stocks of 1,000 u mL−1, 10 µg mL−1
and 100 ng mL−1 respectively. Ferritin from human spleen Type V, 10 µg mL−1 in
0.15 M NaCl, 10 mM Tris, pH 8.0, containing 0.1% NaN3 was purchased from Sigma-
Aldrich.
Samples were shaken using a Thermolyne (AROS160) Adjustable Reciprocating Orbital
Shaker at a speed of 250 rpm at 37 ◦C. Centrifuges apparatus are described when
mentioned. Agarose gel and western blot were imaged using Bio-Rad Universal Hood
II (50/60 Hz, 200 VA). Fast protein liquid chromatography (FPLC) was performed on
a Amersham A˚kta FPLC (loop 2mL, P-920 pump, UPC-900 detector, M-925 mixer,
INV-907 inj. valve, FRAC-900 fraction collector, flow rate up to 20 ml min−1, pressure
0-5MPa (0-725 psi)) and a HiPrep 16/10 DEAE FF from GE Healthcare.
Freeze-thaw cycles were performed using a Thermolyne liquid nitrogen monitor.
Samples heated at 37 ◦C before SDS-PAGE were heated on a Standard Heatblock from
VWR Scientific Products.
OD600 and OD260 were measured on a UV/visible spectrophotometer DU530 from
Beckman Coulter. Autoclaving was performed using Tuttnauer autoclaves.
8.3.1 Transformation of pET-11a and pET-26b(+) into B834(DE3)pLysS
competent cells
LB medium was prepared as 2% LB broth and 1.5% Agar as follows: 500 mL ddH2O +
10 g LB broth + 7.5 g Agar. The mixture was autoclaved at 121 ◦C for 20 min. Plates
were prepared as indicated:
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• for pET-11a: 500 mL LB medium + 100 µL of Amp (20 µg mL−1) + 417 µL of
Chl (25 µg mL−1).
• for pET-26b(+): 500 mL LB medium + 500 µL of Kan (50 µg mL−1) + 417 µL
of Chl (25 µg mL−1).
Both plasmids were dissolved into 50 µL ddH2O. 2 µL of each plasmid were added to
50 µL of competent B834(DE3)pLysS cells. The mixtures were left on ice for 30 min,
heat-shocked at 42 ◦C for 30 s and back on ice for 2 min. 170 µL of SOC (super optimal
catobolite) medium was added to each cell/plasmid sample and place under shaking
at 37 ◦C for 20 min. Cultures were finally spread over plates using glass beads and
incubated at 37 ◦C overnight under shaking.
Positive transformants were grown in 5 mL of LB medium containing 4.17 µL of Chl
(25 µg mL−1) and their respective antibiotics, 1 µL Amp (20 µg mL−1) for pET-11a
and 5 µL Kan (50 µg mL−1) for pET-26b(+).
Each plasmid DNA (2 mL) were purified using the QIAgen spin miniprep kit and a
microcentrifuge. The concentration of the protein was determined by measuring the
optical density (OD) at 260 nm: the H apoferritin produced had a concentration of 309
µg mL−1 and L apoferritin had a concentration of about 380 µg mL−1.
pET-11a and pET-26b(+) (500 µL each) containing genes coding for H and L apofer-
ritins respectively were kept in 50% glycerol (500 µL) at −80 ◦C.
Samples were sent for sequencing to the UC Berkeley DNA Sequencing Facility.[426]
8.3.2 Agarose gel of over-expressed H and L apoferritins
The gel electrophoresis apparatus used was a OWI separation system (model B1A 0-
150 V/0-100 mA) with a power supply FB300 from Fisher Scientific.
The protein ladder 1 kb was purchased from New England Biolabs.
The protein expression was monitored on a 1% agarose gel.
The gel was prepared as followed: 180 mL of ddH2O, 2 g of agarose, 20 mL of 10 ×
TAE (Tris-Acetate-EDTA) to give 1 × TAE. The mixture was heated for 2.5 min at
maximum power in a microwave. It was then allowed to cool down and 3 µL of EtBr
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(stock of 10 mg mL−1) was added.
The running buffer was made by adding 50 mL of 10 × TAE to 450 mL of ddH2O and
a few mL of 1 × TAE + EtBr.
The following samples were loaded onto the gel and the voltage set to 120 V for 1 h 15:
H1 L1 H2 L2
pET-11a (µL) 4 / 2 /
pET-26b(+) (µL) / 4 / 2
TAE (µL) / / 6 6
Loading dye (µL) 1 1 2 2
Total (µL) 5 5 10 10
8.3.3 Large-scale expression of H and L apoferritins
pET-11a and pET-26b(+) vectors kept at −80 ◦C were used to inoculate 100 mL LB
medium + 83.3 µL Chl (25 µg mL−1) containing the respective antibiotics: 25 µL
Amp (20 µg mL−1) for rHuHFt (pET-11a) and 100 µL Kan (50 µg mL−1) for rHuLFt
(pET-26b(+)). The cultures were grown overnight at 37 ◦C under shaking.
The growth was controlled by the OD at 600 nm. After 4 h of growth, IPTG (133 µL,
0.1 M) was added at a final concentration of 37.5 g mL−1 to induce the expression of
the proteins. After 2 h 30, the cells were sedimented for 10 min at 3,080 g (5,000 rpm)
at 4 ◦C using an Avanti centrifuge J26 XP from Beckman Coulter with a J-lite series
JLA-10.500 10,000 rpm rotor. The supernatant was removed and the cell pellet was
kept at −80 ◦C.
8.3.4 SDS-PAGE of the large-scale expression culture of H and L
apoferritins
The gel electrophoresis apparatus used was Bio-Rad Criterion 80 W/600 V with power
supply PowerPac HV 5,000 V/500 mA/400 W from Bio-Rad.
The 2× loading buffer was supplied by Shelton Scientific Incorporation. β-Mercaptoethanol
and Kaleidoscope protein ladder and 10 × Tris/Gly buffer were supplied by Bio-Rad.
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Imperial protein stain was supplied by Thermo Scientific.
The 15% Tris-HCl precast gel was purchased from Criterion Bio-Rad (1 mm, 12 +
2 wells comb, 45 µL). The protein buffer was supplemented by adding 1% of β-
mercaptoethanol (3 µL) to 300 µL of 2 × loading buffer.
The following samples were prepared and heated at 95 ◦C for 10 min: 50 µL ddH2O +
50 µL loading buffer + small amount of H/L cultures frozen at −80 ◦C. The samples
were loaded onto the precast gel and the tank was filled with the running buffer 1 ×
Tris/Gly/SDS (1 ×). The gel was run at 200 V for 1 h 10. The gel was washed 3 times
by shaking 5 min with 100 mL ddH2O and stained by shaking with Imperial protein
stain for 1 h. The gel was finally destained by shaking with 200 mL ddH2O for 1 h 30.
8.3.5 Purification of large-scale expression culture of H human apo-
ferritin
The purification was followed as described by Grace et al. in reference [409]. Cell
pellets were resuspended in 50 mM Tris pH 7.0 with DNase I (20 µg mL−1), RNase
I (µg mL−1) and lysozyme (1 mg mL−1). After 30 min on ice, the suspensions were
subjected to three freeze-thaw cycles (liquid nitrogen for 5 min - water bath at RT for
20 min) and centrifuged at 30,000 g (19,562 rpm, JA-20 rotor) for 30 min to remove
cellular debris. The supernatant was concentrated using a Minicon Ultra-4 centrifugal
filter device from Millipore and centrifuged at 3,320 g (4,000 rpm) at RT using a
Sorvall RT7 Plus centrifuge with rotor RTH-750 until the solution was concentrated to
2 mL. The ultrafiltrate was centrifuged for 10 min at 4,000 g (6,131 rpm) at 4 ◦C using
centrifuge 5417R rotor F 45-30-11 from Eppendorf and then filtered using Millex GP
syringe-driven filter unit 0.22 µm from Millipore.
The suspension was finally applied to a HiPrep 16/10 DEAE FF-Sepharose Fast Flow
anion exchange column. First the FPLC tubing was rinsed with ddH2O (25 mL) at 5
mL min−1 followed by 0.50 mM Tris pH 7.0 containing 300 mM NaCl (5mL) at 5 mL
min−1. The column was then equilibrated with 50 mM Tris pH 7.0 (100 mL) at 5 mL
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min−1. H human apoferritin (2 mL) was injected and eluted with a stepwise gradient
from 50 to 300 mM NaCl in 50 mM Tris pH 7.0. at 3 mL min−1.
The apoferritin-rich fractions were analysed by SDS-PAGE (15% Tris-HCl precast gel)
following the procedure described in section 8.3.4. The following samples were prepared
and heated at 95 ◦C for 10 min:
• fractions B12 to C2 + C5 to C9: 17.5 µL fraction + 17.5 µL loading buffer,
• fractions C3 and C4: 8.75 µL fraction + 8.75 µL ddH2O + 17.5 µL loading buffer,
• human spleen ferritin: 2 µL ferritin + 34 µL ddH2O + 36 µL loading buffer.
The gel was run at 200 V for 1 h, stained and destained as described previously.
8.4 Incorporation of methionine analogues into H and L
human apoferritins
M9 minium salts medium (5 ×), glucose (99%) ZnSO4.7H2O (99%), MnSO4.7H2O
(99%), CuSO4, CoSO4
.7H2O (98%), H3BO3 (99%), Na2MoO4
.2H2O (99.5%), thiamine-
HCl and the kit of 10 essential amino acids (1 g of each: L-arginine hydrochloride, L-
histidine hydrochloride, L-isoleucine, L-leucine, L-lysine hydrochloride, L-methionine,
L-phenylalanine, L-threonine, L-tryptophan, L-valine) were purchased from Sigma-
Aldrich. CaCl2, MgSO4
.7H2O were supplied by Fisher.
Samples were shaken using a Thermolyne (AROS160) Adjustable Reciprocating Or-
bital Shaker at a speed of 250 rpm at 37 ◦C and a refrigerated incubator shaker Innova
4230 from New Brunswick Scientific at a speed of 250 rpm at 20 ◦C.
8.4.1 Preparation of M9 media
The M9 medium was modified by adding a series of salts and glucose as described
below:
1. 200 mL M9 medium (5 ×) were mixed with 800 mL of ddH2O.
2. Salts were added:
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Salts
Stocks Volume Final
solutions (M) added to M9 concentration
CaCl2 0.1 1 mL 0.1 mM
ZnSO4
.7H2O 0.1 80 µL 8.0 µM
MnSO4
.7H2O 0.1 100 µL 10.0 µM
MgSO4
.7H2O 1 1 mL 1.0 mM
CuSO4 0.1 20 µL 2.0 µM
CoSO4
.7H2O 0.1 20 µL 2.0 µM
H3BO3 0.1 10 µL 1.0 µM
Na2MoO4
.2H2O 0.1 10 µL 1.0 µM
Thiamine-HCl 0.001 0.3 µL 0.3 nM
3. Glucose (2%, 20 g) was added.
4. Amino acids (L-arginine hydrochloride, L-histidine hydrochloride, L-isoleucine,
L-leucine, L-lysine hydrochloride, L-phenylalanine, L-threonine, L-tryptophan, L-
valine) were added at 120 mg mL−1.
5. Mixture was stirred at RT.
6. Three M9-based solutions of 100 mL were prepared to each of which was added
a different methionine analogue at a concentration of 120 mg mL−1.
7. M9 medium (1,000 mL) with methionine amino acid was prepared using the same
procedure.
8. M9 medium (1,000 mL) without amino acids was prepared using the same pro-
cedure.
All media were filtered using Express Plus 0.22 µm filters from Millipore.
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8.4.2 Expression of H and L human apoferritins containing methion-
ine analogues.
The protein expression was achieved as described by van Hest et al. in reference [401].
pET-11a and pET-26b(+) vectors kept at −80 ◦C were used to inoculate 5 mL M9
medium (with methionine) + 4.2 µL Chl (25 µg mL−1) containing the respective an-
tibiotics: 1 µL Amp (20 µg mL−1) for rHuHFt (pET-11a) and 5 µL Kan (50 µg mL−1)
for rHuLFt (pET-26b(+)). The cultures were grown overnight at 37 ◦C under shaking.
Small-scale expression was achieved by adding 4 mL of the overnight cultures to M9
medium with all amino acids except methionine (50 mL) + 46 µL Chl (25 µg mL−1)
containing the respective antibiotics: 11 µL Amp (20 µg mL−1) for rHuHFt and 55
µL Kan (50 µg mL−1) for rHuLFt. The cultures were grown overnight at 37 ◦C under
shaking.
The growth was controlled by the OD at 600 nm until the turbidity reached a value of
∼ 0.4 (maximum OD observed in theses conditions). After 5 h,cells were sedimented
for 10 min at 3,320 g (4,000 rpm) at RT using a Sorvall RT7 Plus centrifuge with
rotor RTH-750. The supernatant was removed and the cell pellet was resuspended and
washed twice with M9 without amino acids (20 mL). After removal of the supernatant,
the cell pellet was dissolved in 50 mL of M9 without amino acids and divided into 10
5 mL-aliquots and sedimented.
The aliquots were prepared by resuspending the cell pellets in 5 mL of M9 medium
containing the methionine analogue at 120 mg mL−1 and different protein expressions
were induced as following:
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Protein Incubation IPTG Incubation OD600
H or L apoferritin T ( ◦C) (mM) time (h) H L
positive control 37 0.75 2 0.410 0.451
negative control 37 0.75 2 0.344 0.323
aminohexynoic acid 37 0.75 2 0.387 0.368
azidohomoalanine 37 0.75 2 0.439 0.353
azidonorleucine 37 0.375 2 0.379 0.332
azidonorleucine 37 1.5 2 0.372 0.437
azidonorleucine 37 0.75 2 0.426 0.371
azidonorleucine 37 0.75 4 0.401 0.354
azidonorleucine 20 0.75 o/n 0.361 0.421
All samples were sedimented at 3,000 g for 10 min and the cell pellets were kept at
−80 ◦C.
8.5 Western blot of L human apoferritin containing me-
thionine analogues
The gel electrophoresis apparatus used was Bio-Rad Criterion 80 W/600 V with power
supply PowerPac HV 5,000 V/500 mA/ 400 W from Bio-Rad.
Protein ladder Precision Plus Dual Color Standards and Tween 20 were supplied by
Bio-Rad. Ponceau S solution (0.1% Ponceau S (w/v) in 5% acetic acid (v/v)) and
non-fat dry milk were purchased from Sigma-Aldrich. L apoferritin antibody and goat
anti-rabbit IgG-HRP were purchased from Santa Cruz Biotechnology.
Shaking was performed on Speci-Mix from Thermolyne.
The following solutions were prepared:
• Tris-buffered saline (1 × TBS) (20 mM Tris, 150 mM NaCl, pH 7.5): 30 mL 5 M
NaCl, 20 mL 1 M Tris pH 7.4, 950 mL ddH2O.
• Wash solution (TTBS) (20 mM Tris, 150 mM NaCl, 0.05% Tween 20, pH 7.5):
0.5 mL Tween 20, 1 L TBS.
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• Blocking solution (5% non-fat dry milk in TTBS): 60 mL TTBS, 3 g non-fat dry
milk.
• Transfer buffer (20% v/v methanol): 200 mL MeOH, 100 mL 10 × Tris/Gly, 700
mL ddH2O.
Cell pellets from section 8.4.2 were resuspended in 200 µL of ddH2O + 200 µL of
loading buffer + 0.1% β-mercaptoethanol and heated 2 times 10 min at 95 ◦C to allow
the cells to resuspend properly.
The apparatus was set up as described in the instruction manual of the Criterion Blotter
from Bio-Rad and the transfer was run at 100 V for 30 min in a cold room.
Samples (5 µL) and protein ladder were loaded on SDS-PAGE 15% and the tank was
filled up with buffer 1 × Tris/Gly/SDS and run at 200 V for 1 h 15.
The membrane was rinsed with ddH2O, stained with Ponceau S for 5 min under shaking
and destained with ddH2O. The membrane was then placed in a sealed bag with anti-L
ferritin antibody solution (5 mL of anti-LF in blocking solution, dilution factor 1:200)
and placed under shaking in a cold room for 30 min. The membrane was washed 4
times with ddH2O and placed back in a sealed bag containing the secondary antibody
anti-rabbit IgG (5 mL of goat anti-rabbit IgG:sc2004 in blocking solution, dilution
factor 1:2,000) and placed under shaking in a cold room for 30 min.
The protein bands were finally visualized using a luminescent substrate. The membrane
was equilibrated in 12 mL of 1:1 ratio luminol/enhancer and peroxide buffer for 5 min
and placed in a plastic film for imaging.
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